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A2M α
2
-macroglobulin
AP-1 activator protein-1
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1
-protease inhibitor
BM basement membrane
bp base pair
cDNA complementary deoxyribonucleic acid
CMT chemically modified tetracycline
DNA deoxyribonucleic acid
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TAT tumor-associated trypsin(ogen)
TATI tumor-associated trypsin inhibitor
TIMP tissue inhibitor of metalloproteinases
tPA tissue-type plasminogen activator
uPA urokinase-type plasminogen activator
7Introduction
Trypsinogens and Kazal-type trypsin in-
hibitor, which is also called pancreatic secre-
tory trypsin inhibitor (PSTI) and tumor-
associated trypsin inhibitor (TATI), have
long been considered pancreas-specific. The
main physiological function of pancreatic
trypsin is participation in digestion by deg-
radation of dietary proteins and by activa-
tion of other digestive enzymes such as chy-
motrypsinogen, proelastase, procarboxy-
peptidase, and prophospholipase in the
small intestine. PSTI is thought to prevent
the proteolytic destruction of the pancre-
atic gland by inhibiting prematurely acti-
vated trypsins within the pancreas. How-
ever, it has been shown that trypsinogens
and PSTI/TATI are widely expressed also
outside the gastrointestinal tract which
suggests that they may also have other bio-
logical functions. Furthermore, tumors
originating from various tissues in- and
outside the gastrointestinal tract express
trypsinogens and TATI, and the serum and
urine levels of TATI often increase in pa-
tients with various types of cancer. Increased
proteolytic activity is one of the major fac-
tors needed for tumor invasion and metasta-
sis. Matrix metalloproteinases and plasmi-
nogen activator-plasminogen system have
been the subject of the most intensive re-
search but less is known about the role of
trypsins in the proteolysis associated with
tumor invasiveness. This work was under-
taken to study the expression of trypsino-
gens and PSTI/TATI in urogenital organs
and their tumors and to further elucidate
their role in the proteolytic activity of tu-
mors.
Annukka Paju
8
Review of the literature
1. PROTEOLYSIS AND TUMOR
INVASION
A group of coordinated cellular processes is
responsible for invasion and metastasis, the
most life-threatening aspect of cancer. Ge-
netic changes causing imbalance of growth
regulation lead to uncontrolled proliferation
necessary for both primary tumor growth
and metastatic expansion. However, unre-
strained growth does not, by itself, cause
invasion and metastasis (Chambers and
Matrisian, 1997). To succesfully create a
metastatic colony, a cell or group of cells
must be able to leave the primary tumor,
invade the local host tissue, enter circula-
tion, arrest at the distant vascular bed, ex-
travasate into the target organ interstitium
or parenchyma, and proliferate as a second-
ary colony (Chambers and Matrisian, 1997).
The mammalian organism is divided into
a series of compartments separated by the
extracellular matrix (ECM) consisting of the
basement membrane (BM) and its underly-
ing interstitial stroma (Liotta et al., 1983;
Yurchenco and Schittny, 1990). During the
development of invasive tumors, tumor cells
disobey the social order of organ boundaries
and cross into tissues where they do not
belong. BMs are thin continuous extracel-
lular structures which are present practically
everywhere in the body separating organ
cells, epithelia, and endothelia from inter-
stitial connective tissue. The BMs consist
primarily of type IV collagen, laminin-1 and
heparan sulfate proteoglycan. Other com-
ponents are fibronectin, nidogen, laminin-
Primary tumor
of the kidney Local invasion Migration
Extravasation
Intravasation
Basement
membrane
Epithelial cells
Tumor cells
Stroma
Blood vessel
Endothelium
Figure 1. Schematic picture of the multistep process of tumor invasion and metastasis.
    Lung
metastasis
95, type V collagen, fibrillins, chondroitin
sulfate proteoglycan, and SPARC (secreted
protein acidic and rich in cysteine) (Timpl
and Brown, 1996). Interstitial stroma is
composed primarily of type I, II, and III
collagen, glycoproteins, elastin, fibrillins,
and proteoglycans. The exact constitution
of interstitial stroma depends on the tissue
type (Tryggvason et al., 1987; Prockop and
Kivirikko, 1995).
Increased proteolysis is one of the major
cellular events necessery for invasion and
metastasis (Liotta et al., 1983; Saksela,
1985). Tumor cells and host cells induced
by tumor cells secrete proteolytic enzymes
capable of degrading various components
of the ECM. Proteolytic enzymes are
thought to play a role in several steps of
the metastatic process. They are involved
in the expansion of the primary tumor and
in the dissolution of the local BM and in-
terstitial stroma (Figure 1). They are needed
for intra- and extravasation of lymphatics
and blood vessels, in which the subendot-
helial BM and endothelial cell layer have
to be penetrated. Finally, to be able to form
a metastatic colony in the distant organ,
tumor cells have to invade the interstitial
stroma and parenchyma of the target tis-
sue (Chambers and Matrisian, 1997). Pro-
teolytic enzymes involved in invasion and
metastasis belong to four classes of protein-
ases: 1) Matrix metalloproteinases (MMPs),
2) serine proteinases, 3) cysteine protein-
ases, including the cathepsins, and 4) as-
partic proteinases  (Table I). The uPA-plas-
minogen system and MMPs have been the
subject of the most intensive research.
1.1 Matrix metalloproteinases (MMPs)
MMPs are a family of highly conserved Zn2+
-dependent endopeptidases, which collec-
tively are capable of degrading most com-
ponents of the BM and ECM (Birkedal-
Hansen et al., 1993). At present there are
at least 21 known human MMPs which
participate in many normal biological pro-
cesses (e. g., embryonic development, blas-
tocyst implantation, ovulation, bone re-
Review of the Literature
Table I. Proteinases expressed by tumors.
Proteinase class
Collagenases
Gelatinases
Stromelysins
Membrane-type MMPs
Others
Cathepsin B
Cathepsin L
Cathepsin D
pH-optimum Natural inhibitors
Modified from Koivunen, 1991a. Additional references, Thomas et al., 1989; Roberts et al., 1995.
Matrilysins
Matrix metalloproteinases 7-9 TIMPs, α2-macroglobulin
uPA PAI-1, PAI-2, protease nexin-1,
α2-macroglobulin
tPA PAI-1, PAI-2, α2-macroglobulin
Trypsin PSTI/TATI, α2-macroglobulin, α1-proteinase
inhibitor
Cysteine proteinases 3-5 Cystatins
Serine proteinases 7-9
Aspartic proteinases 3-5 α2-macroglobulin
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modeling, and angiogenesis) and pathologi-
cal processes (tumor invasion and metasta-
sis, arthritis, and periodontal disease)
(Nagase and Woessner, 1999). The mem-
bers of the MMP family can be divided into
six subgroups according to their domain
structure and substrate specificity (Table II)
(Birkedal-Hansen et al., 1993; Birkedal-
Hansen, 1995). Despite of some overlap-
ping, MMPs display clear substrate speci-
ficity: collagenases including fibroblast col-
lagenase (MMP-1), neutrophil collagenase
(MMP-8), and collagenase-3 (MMP-13) are
the principal proteinases capable of initi-
ating degradation of native fibrillar inter-
stitial collagens, i. e., collagen I, II, and III
(Kähäri and Saarialho-Kere, 1997) (Table
II). The 72 kDa gelatinase A and 92 kDa
gelatinase B (MMP-2 and MMP-9, respec-
tively) are thought to play an important
role in the degradation of BM type IV col-
lagen and in the final cleavage of denatured
collagen fibrils, i. e., gelatin. Stromelysins
have a broad substrate specificity, being
capable of degrading fibronectins, laminin,
elastin, proteoglycans and collagens (Chan-
dler et al., 1997; Kähäri and Saarialho-Kere,
1997). Of the recently identified mem-
brane-type MMPs (MT-MMPs), the sub-
strate specificity of MMP-14 is best known
(Table II).
The basic 5-domain prototype structure
of MMPs (Birkedal-Hansen et al., 1993;
Birkedal-Hansen, 1995) comprises 1) a 17-
29 amino acid signal peptide, 2) a 77-87
residue propeptide that contains a free cys-
teine residue, 3) an about 165 residue cata-
lytic domain which contains the Zn2+-bind-
ing site, 4) a 5-50 amino acid proline-rich
hinge region, and 5) an about 200 residue
carboxyterminal hemopexin domain which
determines the substrate specificity. MT-
MMPs have an additional transmembrane
domain which anchors them to the cell sur-
face (Sato et al., 1994). MMP-7 (matrilysin-
1) and MMP-26 (matrilysin-2) lack the
hemopexin-like domain (Birkedal-Hansen,
1995; Uría and Lopéz-Otín, 2000), and
MMP-2 and MMP-9 contain a fibronectin-
like domain which facilitates their binding
to collagen, laminin, and gelatin (Allan et
al., 1995).
1.1.1 Regulation of MMP expression and
activity
Regulation of MMP expression and activ-
ity is exerted at several levels involving tran-
scriptional regulation, intra- and extracel-
lular activation of proMMPs, and inhibi-
tion of MMPs by endogenous inhibitors
(Birkedal-Hansen et al., 1993; Birkedal-
Hansen, 1995; Murphy and Knäuper,
1997).
A) Transcriptional regulation
Many different factors influence the tran-
scription of MMPs, including cytokines,
growth factors, hormones, oncogenic cellu-
lar transformation, and chemical agents, e.
g., phorbol esters. In general, the gene ex-
pression of MMPs is up-regulated by
interleukin-1 (IL-1), tumor necrosis factor-
α (TNF-α), transforming growth factor-α
(TGF-α), epidermal growth factor (EGF),
platelet-derived growth factor (PDGF), ba-
sic fibroblast growth factor (bFGF), nerve
growth factor (NGF), parathyroid hormone,
and endotoxin whereas interferon-γ (IFN-
γ), transforming growth factor-β (TGF-β),
retinoids, and glucocorticoids downregulate
the expression (Birkedal-Hansen et al.,
1993; Borden and Heller, 1997). The ex-
pression of MMP-1, -3, -9, -13, and -14 is
readily inducible by cytokines, hormones
and growth factors whereas expression of
MMP-2 is barely affected by these regula-
tory factors  (Birkedal-Hansen et al., 1993;
Borden and Heller, 1997). Furthermore,
there is evidence to suggest that individual
members or groups of the MMP family are
independently regulated (Brown et al.,
1990; Uría et al., 1998). The mechanism of
transcriptional regulation has been exten-
sively studied and the activator protein-1
11
R
eview
 of the L
iterature
Table II. Human matrix metalloproteinases, their activating capacity, activators, and substrates in the ECM.
Collagenases
Gelatinases
Stromelysins
Membrane-type MMPs
Other  MMPs
Enzyme Mr (kDa) Activated by
Modified from Ding, 1998 and Vaalamo, 2000. ND, not determined. Additional references Sorsa et al., 1997;  Ferry et al., 1997;  Mazzieri et al., 1997; Nagase and
Woessner, 1999; Llano et al., 1999;  Kajita et al., 1999;  Pei, 1999; Stracke et al., 2000;  Uría and López-Otín, 2000; Velasco et al., 2000; English et al., 2001; Lohi et al., 2001.
*Predicted on the basis of the amino acid sequence.
SubstratesActivator of
Matrilysins
Fibroblast collagenase (MMP-1) 52/57 MMP-3, -10, plasmin,
kallikrein, chymase
Collagen I, II, III, VII, VIII, X, gelatin, aggrecan,  nidogen, tenascinMMP-2
Neutrophil collagenase (MMP-8) 75 MMP-3, -10, plasmin Collagen I, II, III, VII, VIII, X, gelatin, aggrecan, fibronectin, lamininND
Collagenase-3 (MMP-13) 53 MMP-2, -3, -10,  -14,
-15, plasmin
Collagen I, II, III, IV, IX, X, XIV, gelatin, aggrecan, perlecan, fibronectin,
laminin, tenascin, fibrillin
MMP-2, -9
72 kDa gelatinase A (MMP-2) 72 MMP-1, -7, -13, -14, -15, -16,
-24, plasmin, human trypsin
Gelatin, collagen I, II, IV, V, VII, X, XI, XIV, aggrecan, fibronectin,
laminin, elastin, vitronectin, fibrillin
MMP-9, -13, -17
92 kDa gelatinase B (MMP-9) 92 MMP-2, -3, -13, plasmin,
elastase, human trypsin
Gelatin, collagen IV, V, VII, X, XIV, aggrecan, nidogen, fibronectin,
elastin, vitronectin, fibrillin
ND
Stromelysin-1 (MMP-3) 60/55 Plasmin, kallikrein, chymase,
tryptase, elastase, cathepsin G
Collagen III, IV, V, IX, X, gelatin, nidogen, aggrecan, perlecan, fibronectin,
laminin, tenascin, elastin, fibrillin
MMP-1, -8, -9, -13
Stromelysin-2 (MMP-10) 60/55 As stromelysin-1 Collagen III, IV, V, gelatin, nidogen, aggrecan, fibronectin, elastinMMP-1, -7, -8, -9, -13
Stromelysin-3 (MMP-11) 58 Furin Fibronectin, lamininND
Metalloelastase (MMP-12) 54 ND Collagen IV, gelatin, nidogen, aggrecan, fibronectin, laminin, elastin,
vitronectin, fibrillin
ND
Matrilysin-1 (MMP-7) 28 MMP-3, plasmin Collagen IV, gelatin, fibronectin, laminin, nidogen, aggrecan, fibronectin,
tenascin, elastin, vitronectin, versican
MMP-2
Matrilysin-2 (MMP-26) 29 MMP-9 ND Collagen IV, gelatin, fibronectin
MT1-MMP (MMP-14) 63 Plasmin, furin Collagen I, II, III, gelatin, nidogen, aggrecan, perlecan, fibronectin, laminin,
tenascin, vitronectin, fibrillin
MMP-2, -13
MT2-MMP (MMP-15) 72 ND Fibronectin, laminin, nidogen, tenascin, aggrecan, perlecanMMP-2, -13
MT3-MMP (MMP-16) 64 ND GelatinMMP-2
MT4-MMP (MMP-17) 70 ND GelatinMMP-2
MT5-MMP (MMP-24) ND73* NDMMP-2
MMP-19 57* ND Gelatin, aggrecanND
Enamelysin (MMP-20) 53* ND Amelogenin, aggrecanND
MMP-23 ND44* NDND
Epilysin  (MMP-28) 56* ND ND ND
MT6-MMP (MMP-25) 34 MMP-2 ND Collagen IV, gelatin, fibronectin
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(AP-1) binding site and polyomavirus en-
hancer A-binding protein-3 (PEA3) motif
present in most MMP genes have been the
focus of intense research (Birkedal-Hansen
et al., 1993). Interaction of these two ele-
ments appears to confer responsiveness to
growth factors, oncogene products and tu-
mor promoters (Gutman and Wasylyk,
1990; Benbow and Brinckerhoff, 1997). It
has been suggested that lack of the regula-
tory elements AP-1 and PEA3 in the pro-
moter region of the MMP-2 gene is respon-
sible for its lack of transcriptional regula-
tion (Huhtala et al., 1990; Tryggvason et
al., 1990; Benbow and Brinckerhoff, 1997).
Regulation of MMP expression in polymor-
phonuclear neutrophils (PMNs) is uniquely
different from that of the other cells. Syn-
thesis of MMP-8 and MMP-9 is already
completed by the time the PMNs enter the
vasculature and any further regulation is
mediated by granule release rather than
transcriptional events (Birkedal-Hansen et
al., 1993).
In addition to soluble factors, cell-ma-
trix and cell-cell interactions are considered
to be key factors in the regulation of MMP
gene expression. Examples include a) induc-
tion of MMP-2 and MMP-14 expression in
endothelial cells, fibroblasts, and neoplas-
tic cells when cultured in type I collagen
gel (Gilles et al., 1997; Haas et al., 1998),
b) induction of MMP-1, -2, and -3 expres-
sion in fibroblasts by a transmembrane gly-
coprotein extracellular matrix metallopro-
teinase inducer (EMMPRIN) expressed on
tumor cell surface (Guo et al., 1997), c) in-
duction of MMP-2 expression in T cells
through very late antigen (VLA-4) - vascu-
lar cell adhesion molecule-1 (VCAM-1) -
mediated adhesion to endothelial cells
(Romanic and Madri, 1994).
B) Activation
Apart from membrane-type MMPs and
MMP-11 (stromelysin-3), which are acti-
vated intracellularly by furin (Pei and
Weiss, 1995; Pei and Weiss, 1996), MMPs
are secreted from cells as inactive zymogens
(Nagase and Woessner, 1999). Binding of
the unpaired cysteine residue in the
propeptide domain with the conserved
Zn2+ ion in the catalytic domain (cysteine
switch)  is thought to be responsible for
maintening the latency of the MMPs
(Springman et al., 1990; Van Wart and
Birkedal-Hansen, 1990; Birkedal-Hansen,
1995; Murphy and Knäuper, 1997). The
catalytic site can be exposed by agents that
are able to dissociate the bond between
cysteine and zinc. Several non-proteolytic
agents such as sulfhydryl-reactive agents,
mercurial compounds, reactive oxygen, and
denaturants can break the bond in vitro. In
vivo, most proMMPs are likely to be acti-
vated by tissue or plasma proteinases or
opportunistic bacterial proteinases (Nagase
and Woessner, 1999). Proteinases such as
trypsin, plasmin, and kallikrein can pro-
cess the proMMP into an active interme-
diate which autocatalytically cleaves itself
to a fully active form. MMP-3 and MMP-
10 (stromelysin-1 and –2) are able to
“superactivate” procollagenases to gener-
ate enzymes with higher specific activity
than the autocatalytically processed forms
(Birkedal-Hansen, 1995).
Although many in vitro models for
proMMP activation exist, the in vivo acti-
vation mechanisms are still poorly under-
stood. In lung carcinomas (Tokuraku et al.,
1995) and brain tumors (Yamamoto et al.,
1996) MMP-14 (MT1-MMP) expression
has been found to correlate with the activa-
tion of proMMP-2, suggesting that MMP-
14 is a physiological activator of proMMP-
2. In an in vivo model of acute lung injury,
on the other hand, neutrophil elastase was
found to be a potential physiological acti-
vator of proMMP-9 (Ferry et al., 1997). Sev-
eral studies emphasize the importance of
tightly regulated cell surface-associated ac-
tivation which is represented by 1) uroki-
nase-type plasminogen activator (uPA)/
uPA-receptor/plasminogen cascade and ac-
13
tivation of MMPs by plasmin (Mignatti et
al., 1986; Murphy et al., 1992; Andreasen
et al., 1997; Mazzieri et al., 1997), and 2)
activation of proMMP-2 by MMP-14 (Sato
et al., 1994) (Figure 2). These cascades are
thought to be of physiological significance
(reviewed by Murphy et al., 1999). Genera-
tion of cell surface-associated plasmin by the
activity of receptor bound uPA on cell
bound plasminogen, is thought to be a key
initiator of MMP activation especially
through the activation of proMMP-3
(prostromelysin-1) (He et al., 1989; Nagase
et al., 1990; Murphy et al., 1999; Ramos-
DeSimone et al., 1999). Active MMP-14 on
the cell surface acts as a second focus of ac-
tivation. It is thought that proMMP-2, tis-
sue inhibitor of matrix metalloproteinase-
2 (TIMP-2), and MMP-14 are concentrated
on the cell surface as a trimolecular com-
plex (Strongin et al., 1995; Murphy et al.,
1999). The initial cleavage is mediated by
free MMP-14. The cleavage destabilises the
structure of the propeptide domain of
proMMP-2 after which autoproteolysis pro-
ceeds to release the rest of the propeptide
domain and fully active MMP-2. MMP-14
may also directly activate proMMP-13 (col-
lagenase-3) (Knäuper et al., 1996; Murphy
et al., 1999). A more likely mechanism is
activation of proMMP-13 by MMP-2
(Knäuper et al., 1996). MMP-2, MMP-3,
and MMP-13 can activate proMMP-9
(Fridman et al., 1995; Shapiro et al., 1995;
Knäuper et al., 1997). Activation of pro-
MMPs is thought to be largely limited to
the pericellular environment where cell-as-
sociated proteinases can function in a
priviledged environment away from an ex-
cess of proteinase inhibitors. The efficiency
of the activating interactions is supposed
to be dependent upon mechanisms for con-
centration of the MMPs at the cell surface
or on the ECM (Murphy et al., 1999).
  active
  MMP-13
proMMP-3
active MMP-3active MMP-2
proMMP-2
MMP-14
cell surface
Plasmin
cell surface
Figure 2. Matrix metalloproteinase activation cascades mediated by cell surface-bound MMP-14 and plasmin.
Modified from Murphy et al., 1999.
proMMP-13
active MMP-9
   proMMP-9
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C) Inhibition
MMP activity is controlled by α
2
-
macroglobulin (Sottrup-Jensen and
Birkedal-Hansen, 1989) and by TIMPs,
which represent a specific regulatory
mechanism in extracellular milieu (Murphy
and Docherty, 1992). To date four members
of the TIMP family (TIMP-1, -2, -3, and -
4) have been identified (Murphy and Werb,
1985; Stetler-Stevenson et al., 1989; Uría
et al., 1994; Greene et al., 1996). Although
these inhibitors have very similar inhibitory
activities against most members of the
MMP family, they differ in many aspects
including interactions with proMMPs,
solubility, regulation of expression, and
tissue-specific expression (reviewed by
Henriet et al., 1999). TIMPs exert a two-
step control on MMPs by their ability not
only to inhibit active enzymes but also to
regulate the activation process. TIMPs
inhibit the activity of MMPs by forming
tight noncovalent 1:1 stoichiometric
complexes with active MMPs. With one
exception, i.e. MMP-14, which is well
inhibited by TIMP-2 and TIMP-3 but not
by TIMP-1 (Will et al., 1996), all members
of the TIMP family have a similar function
toward all MMPs. TIMPs also control the
autocatalytic activation of several proMMPs
(DeClerck et al., 1991; Howard et al., 1991;
Strongin et al., 1993) and have the ability
to form complexes with proenzymes. TIMP-
1 preferentially forms complexes with
proMMP-9 (Goldberg et al., 1992) and
TIMP-2 and TIMP-4 with proMMP-2
(Goldberg et al., 1989). Early experimental
studies indicated an inverse correlation
between TIMP-1 and metastatic potential
in vitro and based on results of human and
mouse tumor models it has been suggested
that the MMP inhibitors exert anti-invasive
and antimetastatic effects (Schultz et al.,
1988; Khokha and Denhardt, 1989).
However, more recent studies suggest that
TIMPs are multi-functional molecules
which may have paradoxical effects on
tumor progression. TIMP-1 and TIMP-2
are both known to have growth factor-like
properties which are separate from their
MMP-inhibitory functions (reviewed by
Gomez et al. 1997).
1.1.2 MMPs in tumor invasion and metasta-
sis
Especially the type IV collagen-degrading
enzymes MMP-2 and MMP-9 have been the
focus of intensive research, because break-
down of the BM is an essential step in can-
cer invasion. In a pioneering study, Liotta
et al. (1980) showed a correlation between
the metastatic potential of tumor cells and
their ability to degrade BM collagen. Since
then, it has been shown that MMPs are
overexpressed in several tumors
(Westermarck and Kähäri, 1999). Transfec-
tion of human bronchial epithelial cells or
rat embryo cells with Ha-ras oncogene re-
vealed that acquisition of the metastatic
phenotype is linked to secretion of type IV
collagenases (Bonfil et al., 1989; Bernhard
et al., 1994). On the other hand, recombi-
nant human TIMP inhibited human am-
nion invasion and lung colonization of mu-
rine B16-F10 melanoma cells (Schultz et al.,
1988) and TIMP-1 inhibited simian virus
40 T antigen-induced hepatocarcinogenesis
by reduction of hepatocellular proliferation
and tumor angiogenesis (Martin et al.,
1999). Recently, Itoh and colleagues (1998;
1999) showed that tumor-induced angio-
genesis, tumor growth and lung coloniza-
tion were suppressed in MMP-2 and MMP-
9 deficient mice, and Koivunen and col-
leagues (1999) showed that synthetic MMP-
2- and MMP-9-inhibitory peptides pre-
vented tumor growth and invasion in mouse
models. The importance of MMP-2 in tu-
mor angiogenesis was further evidenced by
the results of Fang et al. (2000) which im-
plicated MMP-2 activity as a requirement
for the switch of angiogenic phenotype in a
tumor model. High expression of MMPs by
tumors is associated with poor prognosis, e.
15
g.,  MMP-1 in colorectal (Murray et al.,
1996), MMP-2 in cervical (Davidson et al.,
1999), and MMP-7 in esophageal cancer
(Yamashita et al., 2000).
1.2 Plasminogen activators and plas-
min
Plasmin and plasminogen activators belong
to the serine proteinase family. Plasmino-
gen is the single-polypeptide-chain zy-
mogen form of plasmin produced mainly
in the liver. It is a 90 kDa protein with a
carbohydrate content of 2% (reviewed by
Saksela et al., 1985). Its plasma concentra-
tion is approximately 2 µM but 40% of the
plasminogen is localized extravascularly
(Robbins and Summaria, 1970; Mignatti
and Rifkin, 1993). Active plasmin is an 85
kDa protein consisting of 2 disulfide bridge-
linked polypeptide chains. The C-terminal
B-chain of plasmin contains a serine pro-
teinase domain which is responsible for cata-
lytic activity and binding to inhibitors. The
N-terminal A-chain contains 5 kringle do-
mains (Andreasen et al., 1997). Angiostatin,
which has been reported to inhibit angio-
genesis, is a fragment of plasminogen con-
sisting of kringles 1-4 (O’Reilly et al.,
1994). Plasmin has a broad substrate speci-
ficity, and it is able to degrade many ECM
proteins such as fibronectin, vitronectin,
and laminin (Danø et al., 1985). It also ac-
tivates several proMMPs (Eeckhout and
Vaes, 1977; Werb et al., 1977; Murphy et
al., 1992; Mazzieri et al., 1997) (Table II).
Plasminogen is activated by urokinase-
and tissue-type plasminogen activators
(uPA and tPA) which are 68 kDa and 54
kDa glycoproteins (Saksela, 1985). The pri-
mary role of tPA is to generate plasmin for
thrombolysis, whereas uPA generates plas-
min in events involving degradation of the
ECM, e. g., tumor invasion and tissue re-
modeling (Mullins and Rohrlich, 1983;
Danø et al., 1985; Andreasen et al., 1997).
Active uPA consists of 2 disulfide bridge-
linked polypeptide chains, a C-terminal
proteinase domain and an N-terminal A-
chain which contains a kringle and a growth
factor domain (Andreasen et al., 1997). Like
plasminogen, uPA is secreted as an inactive
proenzyme, prouPA, which can be activated
by trace amounts of plasmin (Danø et al.,
1985; Sim et al., 1986). Trypsin-2 (Koi-
vunen et al., 1989), plasma kallikrein, and
blood coagulation factor XIIa (Ichinose et
al., 1986) activate prouPA in vitro. Bind-
ing of prouPA to a cell surface receptor
(urokinase-type plasminogen activator re-
ceptor, uPAR) enhances plasminogen acti-
vation (Stephens et al., 1989; Ellis et al.,
1991).
Plasminogen activation is controlled by
plasminogen activator inhibitors (PAI) -1
and -2 and α
2
-antiplasmin, which belong
to a superfamily of serpins (serine protein-
ase inhibitors) (Ellis et al., 1990). Of these,
PAI-1 appears to play a particularly impor-
tant role in cancer invasion (Danø et al.,
1985; Andreasen et al., 1997). Components
of the uPA-plasminogen system are ex-
pressed in various cancers and the pattern
of their expression varies between different
types of cancer (reviewed by Andreasen et
al., 1997). In colon cancer, for example, uPA
is expressed in fibroblast-like stromal cells,
uPAR in cancer cells and tumor infiltrat-
ing macrophages (Pyke et al., 1991a), and
PAI-1 in endothelial cells located in the
tumor stroma (Pyke et al., 1991b), indicat-
ing coordinated interplay between various
cell types and the proteinases and protein-
ase inhibitors they produce.
1.2.1 uPA-plasmin system in tumor invasion
and metastasis
Several lines of evidence suggest a central
role for the uPA-plasmin system in tumor
invasion. It has been shown that plasmino-
gen and plasmin activity enhance cell mi-
gration in vitro (Ossowski et al., 1973;
Morimoto et al., 1993; Quax et al., 1994)
and that antibodies against uPA inhibit
migration (Morimoto et al., 1993; Quax et
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al., 1994) and invasion through an isolated
human amniotic membrane (Mignatti et al.,
1986). In a pioneering work Ossowski and
Reich (1983) showed that antibodies against
human uPA inhibited lung metastasis of
human tumor cells implanted onto the
chorio-allantoic membrane of chicken em-
bryos. Using a model based on dissemina-
tion of human tumors in nude mice,
Ossowski et al. (1991) reported that anti-
bodies against human uPA prevented local
invasion of cancer cells and Quax et al.
(1991) reported a correlation between can-
cer cell uPA expression and lung metastasis
with a series of melanoma cell lines.
Wilhelm et al. (1995) found that uPA
antisense oligonucleotides inhibited the
intraperitoneal growth of human ovarian
cancer cells in nude mice, and transfection
of rat PC3 prostate carcinoma cells with
uPA cDNA enhanced their metastatic po-
tential in vivo when inoculated into the car-
diac ventricles of rats (Achbarou et al.,
1994). The importance of the uPA-plasmin
system in tumor invasion and metastasis is
reflected by the relationship between the
prognosis of cancer patients and the levels
of uPA, uPAR, PAI-1, and PAI-2 (reviewed
by Andreasen et al., 1997). For example,
uPA has been shown to be a prognostic
marker in several cancers including colo-
rectal (Mulcahy et al., 1994), ovarian (Kuhn
et al., 1994), and breast cancer (Duffy et al.,
1998).
2. TRYPSINOGENS
Trypsinogen is one of the first isolated and
characterized enzymes which has been ex-
tensively studied and used as a model of
protein structure and function. Trypsino-
gen was crystallized from bovine pancreas
by Kunitz and Northrop in 1936,  reported
to occur in human pancreatic juice by
Haverback et al. in 1960 and partially iso-
lated from extracts of human pancreas by
Buck et al. in 1962. Different research
groups have given several names for human
trypsinogens. The nomenclature is summa-
rized in Table III.
Human pancreatic juice contains three
trypsinogen isoenzymes which differ in iso-
electric point (pI) (Scheele et al., 1981)
(Table IV). The most cationic (trypsinogen-
1, pI 6.2) and the most anionic (trypsino-
gen-2, pI 4.9) trypsinogens were purified
from pancreatic juice by Figarella et al. in
1969. Ten years later Rinderknecht et al.
(1979) discovered a minor trypsinogen
isoenzyme, which was characterized by its
intermerdiate electrophoretic mobility and
a pI of 5.7 (Scheele et al., 1981) and there-
fore designated mesotrypsinogen by
Rinderknecht et al. (1984) (trypsinogen-3
in this study). In 1993 Wiegand et al. (1993)
characterized an additional trypsinogen
(trypsinogen-4) expressed exclusively in the
brain. Trypsinogen-4 has been suggested to
be a splicing variant of the gene which en-
codes trypsinogen-3 (Wiegand et al., 1993).
Stenman et al. (1988) detected and Koi-
vunen et al. (1989) isolated from ovarian
tumor cyst fluid two trypsinogens which
probably are encoded by the same genes as
the corresponding pancreatic trypsinogen-
1 and -2 (Sorsa et al., 1997). These tumor-
associated trypsinogens (TATs) are identi-
cal to their pancreatic counterparts in  the
amino-terminal amino acid sequence, im-
munoreactivity and molecular size but dif-
fer in substrate specificity,  susceptibility
to inhibition by protease inhibitors, and pI
(Koivunen et al., 1989) (Table IV).
2.1 Genes, mRNAs, and proteins
By complete genomic sequencing of the
human trypsinogen gene family, 8 trypsi-
nogen genes have been found to be located
in the chromosome region 7q35 and one in
9p13 but only three of them have been
shown to encode a protein (Rowen et al.,
1996). Each trypsinogen gene is composed
of five exons and resides within a tandemly
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duplicated 10 kb segment (Rowen et al.,
1996). The regulatory elements controlling
the transcription of human trypsinogen
genes have not been characterized. However,
pancreas-specific regulatory elements have
been shown to be involved in the transcrip-
tional control of pancreas-specific genes in-
cluding trypsinogen in rat and mouse
(Walker et al., 1983; Cockell et al., 1989;
Fodor et al., 1991). The coding region of
trypsinogen-1, -2, and -3 cDNA consists
of 741 basepairs (bp) (Emi et al., 1986; Tani
et al., 1990; Nyaruhucha et al., 1997) and
that of trypsinogen-4 of 780 bp (Wiegand
et al., 1993). Trypsinogen-1, -2, and -3 are
synthesized as 247 amino acid polypeptides
including a 15 amino acid  signal and an 8
amino acid activation peptide (Guy et al.,
1978) (Figure 3). The a- and b-forms of
trypsinogen-4, which are thought to repre-
sent allelic polymorphism, contain 260 and
259 amino acids, respectively (Wiegand et
al., 1993). Trypsinogens contain 5 disul-
fide bridges (Guy et al., 1978). The molecu-
lar weights of trypsinogens calculated on
the basis of the amino acid content and their
relative molecular masses (M
r
) determined
by SDS-PAGE are listed in Table IV. Trypsi-
nogen-1 and -2 share 92% and 89% iden-
tity at the cDNA and protein level, respec-
tively (Emi et al., 1986). The amino acid
sequence of trypsinogen-3 displays 86% and
88% sequence identity with those of trypsi-
nogen-1 and -2, respectively   (Nyaruhucha
et al., 1997). Trypsinogen-4 cDNA shares
extensive similarity with those of trypsino-
gen-1, -2, and –3 through exons 2-5
whereas exon 1 of trypsinogen-4 is unique.
Unlike other trypsinogen isoenzymes,
trypsinogen-4 has been suggested to be a
T9
Nyaruhucha et al., 1997Mesotrypsi-
nogen
Trypsinogen-2 Scheele et al., 1981
Wiegand et al., 1993TRY IV Trypsinogen-4Trypsinogen-4 Wiegand et al., 1993
Rinderknecht et al., 1984
Tani et al., 1990TRY III Mesotrypsinogen Rinderknecht et al., 1979; Trypsinogen-3
TAT-2 Koivunen et al., 1989
Trypsinogen-1 Scheele et al., 1981
Rinderknecht et al., 1984
Anionic Rinderknecht et al., 1979;
T8 TRY II Emi et al., 1986 Trypsinogen-2 Figarella et al., 1969 Trypsinogen-2
T7 (pseudogene)
T6 (no product)
T5 (pseudogene)
TAT-1 Koivunen et al., 1989
Trypsinogen-3 Scheele et al., 1981
Rinderknecht et al., 1984
Cationic Rinderknecht et al., 1979;
T4 Emi et al., 1986TRY I Trypsinogen-1 Figarella et al., 1969 Trypsinogen-1
Table III. Nomenclature of trypsinogen genes, cDNAs, and proteins.
T1 (pseudogene)
T2 (relic gene)
T3 (pseudogene)
Gene
(Rowen et al., 1996) cDNA ProteinReference Reference
Name used
in this study
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cytoplasmic protein, because a leader se-
quence typical of secreted proteins has not
been found in its first exon (Wiegand et al.,
1993).
2.2 Specificity and regulation of
enzymatic activity
Trypsinogens belong to the serine protein-
ases which are neutral proteinases charac-
terized by a catalytic triad consisting of a
Ser195, His57, and Asp102 (chymotrypsin
numbering) (Craik et al., 1985). The sub-
strate specificity is determined by the sub-
strate binding pocket which consists of con-
served Asp189, Gly216, and Gly226. The
aspartate residue (Asp189) of trypsin forms
a strong electrostatic bond with arginine
and lysine residues of the substrate after
which trypsin hydrolyses the peptide bond
on the carboxyl terminal side of either of
these amino acids. The two glycines in the
substrate binding pocket of trypsin permit
the entry of large amino acid side chains
into the hydrophobic pocket (Craik et al.,
1985). These conserved amino acids of the
human trypsinogens are shown in figure 3.
2.2.1 Activation
During the digestive process, trypsinogens
entering duodenum in pancreatic secretions
are activated by enterokinase (also called
enteropeptidase) - a membrane-bound
serine proteinase in the brush border of
duodenal enterocytes (reviewed by Lu et al.,
1999). Upon activation, trypsinogen-2 lib-
erates an activation peptide Ala-Pro-Phe-
Asp
4
-Lys (Guy et al., 1976) whereas trypsi-
nogen-1 liberates the same octapeptide or a
pentapeptide Asp
4
-Lys (Guy et al., 1978).
During activation, the molecular mass of
trypsinogens decreases by about 1 kDa.
Both trypsin-1 and -2 activate trypsinogen-
1 and -2 at pH 8.0 and 20 mM Ca2+ at the
same rate but the affinity of both trypsins
is higher for trypsinogen-1 than for trypsi-
nogen-2 (Colomb and Figarella, 1979). At
pH 5.6 and 1 mM Ca2+, the autoactivation
of trypsinogen-1 is more efficient than its
activation by enterokinase. Thus under con-
aIsoelectric point of zymogen denatured in 8 M urea
bTheoretical isoelectric point of an active enzyme
cTheoretical molecular weight of zymogen calculated on the basis of amino acid content
dTheoretical molecular weight of active enzyme calculated on the basis of amino acid content
eRelative molecular mass of zymogen determined by SDS-PAGE
b-form 7.7b Wiegand et al., 1993 24 218d Wiegand et al., 1993
a-form 7.5b Wiegand et al., 1993 24 348d Wiegand et al., 1993
Trypsinogen-4
Trypsinogen-3 5.7a Scheele et al., 1981 26 Scheele et al., 1981
TAT-2 Koivunen et al., 19894a 28 Koivunen et al., 1989
28 Scheele et al., 1981
Trypsinogen-2 4.9a Scheele et al., 1981 25 006c Guy et al., 1978 26 ±1 Guy et al., 1978
TAT-1 5-5.5a Koivunen et al., 1989 25 Koivunen et al., 1989
27 Scheele et al., 1981
Relative
molecular
mass (Mr) (kDa)
e
6.2a 23 438cTrypsinogen-1 Scheele et al., 1981 Guy et al., 1978 26±1 Guy et al., 1978
Table IV. Biochemical properties of trypsin(ogen)s.
Protein pI Reference
Theoretical
molecular
weight
Reference Reference
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Figure 3. Amino acid sequences of human trypsinogen-1, -2, -3, and -4. aEmi et al., 1986, bNyaruhucha et al., 1997, cWiegand et al.,
1993. Residues recognized by enterokinase are underlined (Maroux et al., 1971). The three amino acid residues of the catalytic triad
are marked with bold type. The three amino acids determining the substrate specificity are marked with * (Craik et al., 1985).  The
putative site of polymorphism in trypsinogen-4 is marked with two dots (Wiegand et al., 1993). Position at which glycine near the
active site serine in trypsinogen-1 and -2 is substituted by arginine in trypsinogen-3 and -4 is marked with ** (Nyaruhucha et al.,
1997).
Trypsinogen-1a          --MNPLL-ILTFVAA---------- ALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQ 56
Trypsinogen-2a          --MNLLL-ILTFVAA---------- AVAAPFDDDDKIVGGYICEENSVPYQVSLNSGYHFCGGSLISEQ 56
Trypsinogen-3b          --MNPFL-ILAFVGA---------- AVAVPFDDDDKIVGGYTCEENSLPYQVSLNSGSHFCGGSLISEQ 56
Trypsinogen-4 (a-form)c LELHPLLGGRTWRAARDADGCEALG TVAVPFDDDDKIVGGYTCEENSLPYQVSLNSGSHFCGGSLISEQ 69
Trypsinogen-4 (b-form)c MELHPLLGGRTWRAARDADGCEALG TVAVPFDDDDKIVGGYTCE-NSLPYQVSLNSGSHFCGGSLISEQ 68
Trypsinogen-1a          WVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVST 125
Trypsinogen-2a          WVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPKYNSRTLDNDILLIKLSSPAVINSRVSA 125
Trypsinogen-3b          WVVSAAHCYKTRIQVRLGEHNIKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVST 125
Trypsinogen-4 (a-form)c WVVSAAHCYKTRIQVRLGEHNIKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVST 138
Trypsinogen-4 (b-form)c WVVSAAHCYKTRIQVRLGEHNIKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVST 137
Trypsinogen-1a          ISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKD 194
Trypsinogen-2a          ISLPTAPPAAGTESLISGWGNTLSSGADYPDELQCLDAPVLSQAECEASYPGKITNNMFCVGFLEGGKD 194
Trypsinogen-3b          ISLPTAPPAAGTECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKD 194
Trypsinogen-4 (a-form)c ISLPTAPPAAGTECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKD 207
Trypsinogen-4 (b-form)c ISLPTAPPAAGTECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKD 206
Trypsinogen-1a          SCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS 247
Trypsinogen-2a          SCQGDSGGPVVSNGELQGIVSWGYGCAQKNRPGVYTKVYNYVDWIKDTIAANS 247
Trypsinogen-3b          SCQRDSGGPVVCNGQLQGVVSWGHGCAWKNRPGVYTKVYNYVDWIKDTIAANS 247
Trypsinogen-4 (a-form)c SCQRDSGGPVVCNGQLQGVVSWGHGCAWKNRPGVYTKVYNYVDWIKDTIAANS 260
Trypsinogen-4 (b-form)c SCQRDSGGPVVCNGQLQGVVSWGHGCAWKNRPGVYTKVYNYVDWIKDTIAANS 259
Signal peptide
cleavage
Propeptide
cleavage
*
****
Exon 1 Exon 2
..
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ditions which are close to the physiological
milieu in duodenum, enterokinase initiates
trypsinogen activation but subsequently
activation of trypsinogen by trypsin pre-
dominates (Colomb and Figarella, 1979).
Furthermore, bile salts and bile acids en-
hance autocatalytic activation of trypsino-
gen (Sarkany and Moreland, 1985). Enter-
okinase is not known to occur in tissues
other than the intestine and it is at present
unclear how trypsinogens are activated in
tissues lacking enterokinase. Trypsinogen
can be activated in vitro also by cathepsin B
(Greenbaum et al., 1959; Figarella et al.,
1988) but the in vivo significance of this
finding is unknown. Cathepsin B has also
been suggested to participate in the pre-
mature activation of trypsinogen in pancre-
atitis (Halangk et al., 2000).
Trypsinogen-1 and -2 have two Ca2+
binding sites and the pK(Ca2+) values of
these sites are different for trypsinogen-1
and -2 (Colomb and Figarella, 1979). The
primary Ca2+ binding site which is common
to trypsin and trypsinogen protects the
molecule against autolysis and thermal de-
naturation. The differences in pK(Ca2+) val-
ues may explain why  trypsin-1 is more re-
sistant to autolysis than trypsin-2. The sec-
ondary Ca2+ binding site in the N-terminal
activation peptide regulates the autoactiva-
tion of trypsinogens. Under physiological
conditions this Ca2+ binding site is unsat-
urated in trypsinogen-2 whereas it is prob-
ably saturated in trypsinogen-1 which re-
sults in more rapid autoactivation of trypsi-
nogen-1 (Colomb and Figarella, 1979).
2.2.2 Inhibition
The main naturally occuring inhibitors of
trypsins are α
2
-macroglobulin (A2M), α
1
-
proteinase inhibitor (API), which is also
called α
1
-antitrypsin (AAT), and the Kazal-
type trypsin inhibitor (Kazal et al., 1948)
which is also called pancreatic secretory
trypsin inhibitor (PSTI) (Pubols et al., 1974)
and tumor-associated trypsin inhibitor
(TATI) (Huhtala et al., 1982). Unlike other
trypsins, trypsin-3 (mesotrypsin)  shows
unique resistance against naturally occuring
trypsin inhibitors (Rinderknecht et al.,
1984; Nyaruhucha et al., 1997). It has been
suggested that substitution of the amino
acid Gly198 in trypsin-1 and trypsin-2,
which normally participates in the interac-
tion with trypsin inhibitors such as
aprotinin (Perona et al., 1993), by a posi-
tively charged Arg in trypsin-3 may inter-
fere with the trypsin-trypsin inhibitor in-
teraction (Nyaruhucha et al., 1997) (Figure
3). A2M is a 720 kDa proteinase inhibitor
which reacts with a large variety of protein-
ases (Barrett and Starkey, 1973) and is the
predominant inhibitor of trypsin in serum
(Ohlsson, 1988). It is synthesized mainly
in the liver (Laurell and Jeppson, 1975) but
also in monocytes (Hovi et al., 1977) and
macrophages (White et al., 1980). In
plasma, the average A2M concentration is
2 g/l (3 µM) (Ganrot, 1967; Birkenmeier
and Stigbrand, 1993). API is a 51 kDa
serpin synthesized in the liver (Carrell et al.,
1982). It is quantitatively the dominating
proteinase inhibitor in plasma. It inhibits
several proteinases but its major physiologi-
cal target is thought to be neutrophil
elastase. In plasma, the average API con-
centration is 1.3 g/l (26 µM) (Carrell et al.,
1982). PSTI/TATI is a very specific trypsin
inhibitor which is thought to prevent in-
appropriate activation of trypsinogen in the
pancreas (Haverback et al., 1960; Greene et
al., 1976) and in other tissues expressing
trypsinogen and PSTI/TATI (Stenman et al.,
1991). PSTI/TATI is described in detail in
Chapter 3.
2.3 Expression of trypsinogens
2.3.1 Occurrence of trypsinogens in various
body fluids
Trypsinogen-1 and -2 represent about 19%
of the total protein in pancreatic juice, and
trypsinogen-1 is present at concentrations
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twice those of trypsinogen-2 (Figarella et al.,
1969; Guy et al., 1978). The minor isoen-
zyme, trypsinogen-3, occurs at very low
concentrations and represents < 0.5% of the
proteins in normal human pancreatic secre-
tions (Rinderknecht et al., 1984). In serum
of healthy subjects, average trypsinogen-1
and -2 concentrations of 15 to 26 µg/l
(Borgström and Ohlsson, 1976; Geokas et
al., 1979; Florholmen et al., 1984) and 5.5
µg/l (Largman et al., 1978), respectively,
have been reported. Trypsins were found for
the first time outside the gastrointestinal
tract by Stenman et al. (1988) from cyst flu-
ids of ovarian tumors in which they occur
at high concentrations, i. e., up to 2600 µg/
l (Koivunen et al., 1990). Low concentra-
tions of trypsinogen-1 and -2 isoenzymes
with pI values similar to those of pancre-
atic and tumor-associated isoenzymes can
be detected in serum of pancreatectomized
patients, which indicates that trypsinogens
in serum are not only of pancreatic origin
(Itkonen et al., 1996). Trypsinogen-4 has
recently been detected in cerebrospinal fluid
of patients with aneurysms (Critchley et al.,
2000).
2.3.2 Expression in the pancreas and extra-
pancreatic tissues
Pancreatic trypsinogen is produced in the
acinar cells of the exocrine pancreas and
stored in the secretory vesicles, from where
it is secreted into the pancreatic duct in re-
sponse to hormonal and neural stimuli
(Eddeland and Wehlin, 1978; Dooley and
Valenzuela, 1984; Owyang et al., 1986).
Trypsinogen-1 and -2 immunoreactivity
was first detected outside the pancreas in
Paneth cells in the mucosa of the normal
small intestine, gastric mucosa with intes-
tinal metaplasia, and colonic metaplastic
mucosa (Bohe et al., 1986). Recently, trypsi-
nogen-2 expression was detected in vascu-
lar endothelial cells (Koshikawa et al.,
1997). Koshikawa et al. (1998) detected
trypsinogen expression at the mRNA and
protein level in epithelial cells of the skin,
esophagus, stomach, small intestine, lung,
kidney, liver, and extrahepatic bile duct, as
well as splenic and neuronal cells. The iden-
tity of the trypsinogen isoenzyme(s) was not
revealed in that study. In the esophagus,
trypsinogen was detected in the basal and
para-basal cells of the stratified squamous
epithelium whereas in the skin, trypsino-
gen was found to be evenly distributed from
the basal cells to the stratum spinous cells.
In the kidney, trypsinogen was detected in
the collecting ducts and in the lung, in
bronchial and bronchiolar epithelial cells.
In the liver, hepatocytes were shown to be
the site of trypsinogen synthesis and in the
spleen trypsinogen expression was detected
in macrophages, monocytes, and lympho-
cytes in the white pulp. In the brain, trypsi-
nogen was detected in the nerve cells of the
hippocampus and cerebral cortex (Koshi-
kawa et al., 1998).
Tumor-associated trypsinogens were first
demonstrated in ovarian neoplasms by Koi-
vunen et al. (1989). Later, trypsinogens have
been shown to be expressed in several can-
cers. Gastric (Fujimura et al., 1998) and
colorectal cancer (Oyama et al., 2000) ex-
press trypsinogen-1. Ovarian (Hirahara et
al., 1995; Hirahara et al., 1998) and pan-
creatic cancer (Ohta et al., 1994), cholan-
giocarcinoma (Terada et al., 1995), and lung
neoplasms (Kawano et al., 1997) express
trypsinogen. In these studies the identity
of trypsinogen isoenzyme(s) was not speci-
fied. Cancer cell lines derived from colon
(Koivunen et al., 1991b; Bernard-Perrone
et al., 1998; Oyama et al., 2000), pancre-
atic (Miszczuk-Jamska et al., 1991; Ohta et
al., 1998) and gastric cancer (Koshikawa et
al., 1992; Koshikawa et al., 1994; Kato et
al., 1998; Miyata et al., 1998) express trypsi-
nogen-1 and -2 whereas fibrosarcoma and
erythroleukemia cells mainly express trypsi-
nogen-2 (Koivunen et al., 1991b). Cultured
ovarian cancer cells express trypsinogen, the
identity of which was not specified (Hira-
hara et al., 1995). Hirahara et al. (1998)
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studied samples of ovarian tumors and
found that the incidence of immunoreac-
tive trypsinogen was higher in ovarian car-
cinomas than in borderline tumors whereas
normal ovaries were negative. However, in
ovarian carcinomas the incidence of trypsi-
nogen positivity was high in early (6/11,
55%) as well as in advanced tumors (8/10,
44%) (Hirahara et al., 1998). Ohta et al.
(1994) detected trypsinogen expression
immunohistochemically in 15 of 20 (75%)
invasive tubular pancreatic adenocarcino-
mas and their metastatic lesions but not in
three non-invasive intraductal papillary
adenocarcinomas. They did not find corre-
lation between trypsinogen expression and
the histological differentiation of the tumor.
Terada et al. (1995), on the other hand,
found trypsinogen immunoreactivity in 26
of 37 (70%) cholangiocarcinomas and the
incidence of trypsinogen immunoreactivity
was higher in well-differentiated than in
poorly differentiated cholangiocarcinomas.
Although trypsinogen immunoreactivity
was also detected in normal liver, it was not
observed in any of the 36 hepatocellular
carcinomas studied (Terada et al., 1995).
Recently, trypsinogen immunoreactivity
was found by Oyama et al. (2000) in 69 of
154 (44%) colorectal cancers preferentially
at the invasive front of the cancer. They did
not find statistically significant relationship
between the trypsinogen expression and the
clinicopathological findings.
There are few studies concerning the
regulation of trypsinogen expression. Koi-
vunen et al. (1991b) showed that the anti-
inflammatory glucocorticoid dexametha-
sone downregulated trypsinogen-2 produc-
tion by HT 1080 fibrosarcoma cells whereas
that by COLO 205 colon carcinoma cells
was not affected. The unresponsiveness of
COLO 205 cells was possibly due to absence
of glucocorticoid receptors. Alternatively
trypsinogen expression may be differently
regulated in different cell types (Koivunen
et al., 1991b). Koshikawa et al. (1997) stud-
ied the expression of trypsinogen-2 in vas-
cular endothelial cells and found that tu-
mor promoter 12-O-tetradecanoylphorbol-
13-acetate (TPA) stimulated trypsinogen-
2 expression and secretion whereas TNF-
α, TGF-α, and IL-1β had no effect. Sup-
pression or induction of MMP expression
by glucocorticoids, tumor promoters, and
cytokines is mediated by the AP-1 site in
the MMP gene (Angel et al., 1987; Jonat et
al., 1990; Birkedal-Hansen et al., 1993).
Whether the AP-1 site is present in the
trypsinogen gene is not known.
2.4 Biological functions of trypsins
Pancreatic trypsin mediates proteolysis of
dietary proteins. Furthermore, it is the key
enzyme for activation of the proenzymes
chymotrypsinogen, proelastase, procarboxy-
peptidases A and B, and prophospholipase
A.
In addition to its well known function
as a digestive enzyme, trypsin probably
plays a role also in other physiological and
pathological processes. Both human pancre-
atic trypsin-1 and -2 and tumor-associated
trypsin-1 and -2 activate prouPA (Koivunen
et al., 1989). Furthermore, human pancre-
atic and tumor-associated trypsin-2 are very
efficient activators of proMMP-9 and they
also activate proMMP-2 although less effi-
ciently (Sorsa et al., 1997). Bovine trypsin,
which has been widely used to study the
activation of proteolytic enzymes, activates
several proMMPs, e. g.,  proMMP-1
(Wilhelm et al., 1986), proMMP-2 (Liotta
et al., 1981), proMMP-3 (Wilhelm et al.,
1987), proMMP-7 (matrilysin-1) (Imai et
al., 1995), proMMP-9 (Duncan et al.,
1998), and the soluble domain of proMMP-
14  (Will et al., 1996). Bovine trypsin also
activates the proform of prostate-specific an-
tigen (PSA) (Takayama et al., 1997).
Recently, it has been shown that bovine
trypsin and human trypsin activate protein-
ase-activated receptor-2 (PAR-2) (Kong et
al., 1997; Nguyen et al., 1999; Alm et al.,
2000; Miyata et al., 2000) which is a G-
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protein-coupled seven-transmembrane do-
main receptor widely expressed in various
epithelial tissues, endothelial cells, T cells,
and tumor cells lines (Nystedt et al., 1995;
Santulli et al., 1995; Böhm et al., 1996; Dery
et al., 1998). PARs induce G protein-me-
diated signal transduction by stimulating
generation of inositol-1, 4, 5-triphosphate
and intracellular Ca2+ mobilization (Santulli
et al., 1995; Böhm et al., 1996; Dery et al.,
1998). Through activation of PAR-2,
trypsin stimulates integrin α
5
β
1
-dependent
adhesion to fibronectin and proliferation of
human gastric carcinoma cells (Miyata et al.,
2000) and possibly regulates enterocytes in
the intestinal lumen by triggering arachi-
donic acid release and prostaglandin secre-
tion (Kong et al., 1997). Trypsin also acti-
vates pancreatic duct epithelial cell ion
channels through PAR-2 which suggests
that prematurely activated trypsin in the
inflamed pancreas may act in paracrine
manner to regulate ion transport by ductal
cells in pancreatitis (Nguyen et al., 1999).
It has also been shown that trypsin stimu-
lates TNF-α and IL-1β production of rat
peritoneal macrophages indicating a link
between increased activity of pancreatic
proteinases and inflammatory cytokine pro-
duction, which both are markedly associ-
ated with acute pancreatitis (Lundberg et
al., 2000).
2.5 Clinical aspects
2.5.1 Pancreatitis
Prematurely activated trypsin is thought to
play a key role in acute pancreatitis
(Whitcomb, 1999). In the normal state,
inactive trypsinogen is stored in cytoplas-
mic zymogen granules of the pancreatic aci-
nar cells and delivered through the pancre-
atic duct to the small intestine where it
becomes activated by enterokinase. In acute
pancreatitis, intracellular activation of
trypsin triggers activation of other pancre-
atic enzymes which leads to autodigestion
of the pancreas (Steer and Meldolesi, 1988;
Whitcomb, 1999). Small amounts of active
trypsin is normally generated within the
pancreas but it is usually rapidly inactivated
by PSTI. If trypsin activity overwhelms the
inhibitory potential of PSTI, trypsin is
thought to be inactivated proteolytically by
trypsin-3 or by autolysis (Whitcomb et al.,
1996). Recently, hereditary pancreatitis was
linked to chromosome region 7q35, and the
defect was found to be caused by mutations
in the trypsinogen-1 gene which may ren-
der trypsin-1 resistant to inactivation by
proteolysis (Whitcomb et al., 1996; Gorry
et al., 1997). Mutations in the PSTI gene
have also recently been found to be associ-
ated with chronic pancreatitis possibly by
rendering PSTI a less efficient inhibitor of
trypsin (Chen et al., 2000; Witt et al., 2000).
The serum levels of trypsinogen-1 and -2
and their API complexes increase in patients
with pancreatitis (Elias et al., 1977; Itkonen
et al., 1990; Hedström et al., 1994), and
serum trypsin-2-API, which reflects release
of active trypsin into circulation, is a prog-
nostic factor for the disease (Hedström et
al., 1996).
2.5.2 Cancer
Several lines of evidence suggest that
trypsins play a role in the proteolytic activ-
ity of tumors. Trypsinogen-1 and -2 are ex-
pressed in several cancers (Koivunen et al.,
1989; Ohta et al., 1994; Hirahara et al.,
1995; Terada et al., 1995; Kawano et al.,
1997; Hirahara et al., 1998; Fujimura et al.,
1998), cancer cell lines (Koivunen et al.,
1991b; Miszczuk-Jamska et al., 1991; Ko-
shikawa et al., 1994; Bernard-Perrone et al.,
1998; Kato et al., 1998; Miyata et al., 1998;
Ohta et al., 1998), and in vascular endothe-
lial cells (Koshikawa et al., 1997). Trypsi-
nogen and trypsin-API levels in serum in-
crease in patients with pancreatic, gastric,
colorectal, hepatocellular, and biliary tract
cancer (Hedström et al., 1996; Hedström et
al., 1999; Ichikawa et al., 2000; ) and trypsi-
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nogen-2 concentrations are significantly
higher in cyst fluids of malignant than of
benign ovarian tumors (Koivunen et al.,
1990).
Human trypsin activates prouPA (Koi-
vunen et al., 1989), proMMP-2, and
proMMP-9 (Sorsa et al., 1997) which play
central roles in angiogenesis, tumor inva-
sion, and metastasis (Andreasen et al., 1997;
Westermarck and Kähäri, 1999). Degrada-
tion of ECM and fibronectin by trypsino-
gen-2-producing cancer cells (COLO 205
colon carcinoma, K-562 erythroleukemia,
CAPAN-1 pancreatic carcinoma, and HT
1080 fibrosarcoma) can be partially inhib-
ited by PSTI/TATI and anti-trypsinogen
antibodies and enhanced by enterokinase
(Koivunen et al., 1991c). Overexpression of
trypsinogen by gastric cancer cells is asso-
ciated with increased tumorigenicity of the
cells in nude mice (Kato et al., 1998; Miyata
et al., 1998).
3. PSTI/TATI
The Kazal-type trypsin inhibitor was origi-
nally extracted from bovine pancreas by
Kazal et al. (1948) and detected in human
pancreatic juice by Haverback et al. (1960).
It was characterized and renamed pancre-
atic secretory trypsin inhibitor (PSTI) by
Pubols et al. (1974). Tumor-associated
trypsin-inhibitor (TATI) was first found in
urine of ovarian cancer patient by Stenman
et al. (1982) and characterized by Huhtala
et al. (1982). The human genome contains
only one PSTI gene  (Horii et al., 1987) and
PSTI cDNAs isolated from the pancreas
(Yamamoto et al., 1985) and neoplastic tis-
sues (Tomita et al., 1987) are identical. Thus
PSTI and TATI are encoded by the same
gene. In this study the name PSTI is used
when the pancreatic inhibitor is discussed
whereas the name TATI is used when it is
emphasized that the inhibitor originates
from a tumor.
3.1 Gene, mRNA, and protein
The PSTI/TATI gene is approximately 7.5
kb long, it comprises 4 exons and is located
on chromosome 5 (Horii et al., 1987). The
gene has multiple transcription start points
(Horii et al., 1987). It lacks the common
transcription regulation sites TATA, CAAT,
and GC boxes but the sequences ATAT and
CAATCAAT lie at -87-84 and -149-142,
respectively, in the promoter region of the
gene (Horii et al., 1987). Yasuda et al. (1998)
have suggested that a sequence
CAATCAATAAC at -149-139 in the pro-
moter region of PSTI gene represents a pan-
creas-specific regulatory element. The PSTI/
TATI gene also contains an interleukin-6
responsive element (IL6RE) and an AP-1-
binding site (Ohmachi et al., 1993; Yasuda
et al., 1993). The PSTI/TATI gene encodes
an mRNA of 237 bp (Yamamoto et al.,
1985) which is translated to 79 amino acid
peptide including a 23 amino acid signal
peptide (Horii et al., 1987). The secreted
PSTI/TATI consists of 56 amino acids, has
three intramolecular disulfide bridges
(Bartelt et al., 1977), and a molecular weight
of 6240 calculated on the basis of the amino
acid composition (Pubols et al., 1974).
PSTI/TATI isolated from urine of an ova-
rian cancer patient was microheterogeneous
in charge and the pI of the main compo-
nent was 5.8 (Huhtala et al., 1982).
3.2 Mechanism of inhibition
PSTI/TATI inhibits trypsin in a 1:1 molar
ratio (Greene et al., 1966; Pubols et al.,
1974). It possesses a reactive site consist-
ing of lysine-18 and isoleucine-19 in the
mature peptide, which serves as a specific
target substrate for trypsin (Bartelt et al.,
1977). The inhibition is reversible (Fritz et
al., 1967) due to proteolytic inactivation of
PSTI/TATI by cleavage of the peptide bonds
Arg42-Lys43 and Arg44-Gln45 (Kikuchi
et al., 1989). After addition of the PSTI-
trypsin complex to serum, PSTI is released
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and most of the trypsin is found in com-
plex with A2M and API (Eddeland and
Ohlsson, 1978a). The mechanism by which
the PSTI-trypsin complex dissociates is not
clear. The three-dimensional structure of the
complex between porcine PSTI and bovine
trypsin has been determined by Bolognesi
et al. (1982).
3.3 Expression of PSTI/TATI
3.3.1 Occurrence of PSTI/TATI in various
body fluids
PSTI represents about 0.1 to 0.8% of the
total protein in pancreatic juice (Pubols et
al., 1974). The mean concentration of PSTI/
TATI in serum of healthy subjects as deter-
mined by radioimmunoassays was 8.1 µg/l
(Eddeland and Ohlsson, 1978b) and 11.3
µg/l (Stenman et al., 1982). By an immuno-
fluorometric assay the mean concentration
of PSTI/TATI in serum of healthy subjects
was 6.9 µg/l and the reference range was
3.1-16 µg/l (Osman et al., 1993). By a ra-
dioimmunoassay, the mean PSTI/TATI con-
centration in urine of healthy subjects was
14 µg/l (Eddeland and Ohlsson, 1978b) and
22 µg/g creatinine (range 7-50 µg/g creati-
nine) (Huhtala et al., 1983). The serum
PSTI/TATI level remains within the nor-
mal range after total pancreatectomy (Halila
et al., 1985). In second trimester amniotic
fluid the median concentration was 160 µg/
l (Kolho et al., 1986). TATI occurs at high
concentrations in cyst fluids of ovarian tu-
mors. The median TATI concentration was
2700 µg/l in benign and 6600 µg/l in ma-
lignant mucinous cyst fluids (Koivunen et
al., 1990).
3.3.2 Expression in the pancreas and extra-
pancreatic tissues
PSTI is secreted together with trypsinogen
from pancreatic acinar cells into pancreatic
juice (Kazal et al., 1948). Like trypsinogen,
PSTI/TATI is also widely expressed in ex-
trapancreatic tissues especially in the gas-
trointestinal and urinary tract. Immunore-
active PSTI/TATI has been detected in
mucus-producing cells of the small intes-
tine, colon, and stomach, as well as in the
gall bladder, kidney and lung (Bohe et al.,
1986; Fukayama et al., 1986; Shibata et al.,
1986; Shibata et al., 1987; Bohe et al., 1990;
Freeman et al., 1990a; Marchbank et al.,
1996). Expression of PSTI/TATI in the gas-
trointestinal tract, kidney, and in the aci-
nar cells of the breast has been demonstrated
both at the mRNA and protein level
(Marchbank et al., 1996). The regulatory
mechanisms of PSTI expression and secre-
tion in extrapancreatic tissues are not
known.
TATI was first demonstrated in gyneco-
logical cancers, i. e., ovarian, cervical, and
endometrial cancer by Stenman et al. (1982)
and Huhtala et al. (1982; 1983). Later, TATI
has been shown to be expressed in pancre-
atic (Ogawa et al., 1987), colorectal (Ogawa
et al., 1987; Higashiyama et al., 1990a;
Tomita et al., 1990), gastric (Ogawa et al.,
1987; Higashiyama et al., 1990b), liver
(Ogawa et al., 1987; Ohmachi et al., 1993),
lung (Ogawa et al., 1987; Tomita et al.,
1987; Higashiyama et al., 1992), breast
(Ogawa et al., 1987), endometrioid, cervi-
cal, and ovarian cancer (Ueda et al., 1989),
and in carcinoma of gall bladder (Bohe et
al., 1991). Cancer cells derived from pan-
creatic (Ogawa et al., 1987; Ogata and
Murata, 1988), gastric, ovarian, lung, liver
(Ogawa et al., 1987), and colon cancer
(Ogawa et al., 1987; Koivunen et al., 1991b)
produce TATI. In gastric carcinoma of in-
testinal-type, a stronger TATI immunore-
activity was observed in advanced carcino-
mas (90%) than in early carcinomas (63%).
In gastric carcinoma of diffuse-type the in-
cidence of immunoreactive TATI was high
in both advanced (85%) and early carcino-
mas (93%) (Higashiyama et al., 1990b). In
colorectal cancer, the incidence of immu-
noreactive TATI was found to correlate with
the depth of invasion and histological dif-
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ferentiation, the incidence being higher in
more invaded and better differentiated car-
cinomas than in less invasive and poorly dif-
ferentiated carcinomas (Higashiyama et al.,
1990a). However, the expression of TATI
mRNA did not correlate with progression
or histological differentiation of colorectal
cancer (Tomita et al., 1990). Furthermore,
in the study of Bohe et al. (1990) immu-
noreactive TATI was not found in neoplas-
tic colonic mucosa whereas it was detected
in normal colonic mucosa. In mucinous ova-
rian tumors the incidence of TATI immu-
noreactivity was higher in benign (80%)
than in malignant tumors (43%)  (Ueda et
al., 1989). In pulmonary adenocarcinoma
the TATI immunoreactivity seemed to be
more frequent in early than in advanced ad-
enocarcinomas.  It was also higher in those
with well or moderate histological differen-
tiation than in those with poor histological
differentiation (Higashiyama et al., 1992).
These studies suggest that TATI expression
is differently regulated in malignancies aris-
ing from different tissues.
3.4 Biological functions of PSTI/TATI
The main physiological function of PSTI is
thought to be the protection of the pancreas
from destruction by inadvertently activated
trypsin (Haverback et al., 1960; Greene et
al., 1976). Identification of trypsinogen and
PSTI/TATI expression in mucus-producing
cells of the gastrointestinal tract has led to
a suggestion that PSTI/TATI is also impor-
tant in preventing excessive digestion of the
gastrointestinal mucus (Freeman et al.,
1990b; Playford et al., 1991; Marchbank et
al., 1996). It has been suggested that PSTI/
TATI plays a role in maintaining mucosal
integrity and in stimulating epithelial re-
pair (Marchbank et al., 1996; Marchbank et
al., 1998). It may also participate in tumor
scar formation (Higashiyama et al., 1992).
In addition to trypsin, PSTI/TATI effi-
ciently inhibits acrosin (Huhtala, 1984)
thus possibly playing a role in reproduc-
tion.
In tumors producing both TATI and
trypsinogen, TATI may have a similar func-
tion as in the pancreas, i. e., protection of
the tumor against the destructive activity
of trypsin within tumor cells (Stenman et
al., 1991). Large amounts of proteinases
may also cause degradation of ECM to an
extent that is detrimental to the adhesion
needed for cell migration (Andreasen et al.,
1997). Although high concentrations of
TATI may protect the ECM against trypsin-
mediated proteolysis so that invasion be-
comes inhibited, it may at lower concen-
trations protect ECM to an extent which is
needed for cell adhesion. This may explain
the observation that patients which have
non-mucinous ovarian cancer and elevated
TATI levels in serum have worse prognosis
than those with normal TATI levels
(Venesmaa et al., 1998).
PSTI/TATI has been proposed to exert
growth factor-like properties. This possibil-
ity was raised when it was discovered that
PSTI/TATI and epidermal growth factor
(EGF) are of similar size, share significant
amino acid sequence homology and have
three disulfide bridges (Hunt et al., 1974;
Scheving, 1983). In spite of the homology
at cDNA and amino acid sequence level,
the structures of PSTI/TATI and EGF genes
are so different that they are not thought to
be derived from a common ancestral gene
(Horii et al., 1987). PSTI/TATI binds to a
cell surface receptor, which is distinct from
EGF receptor (Niinobu et al., 1986;
Niinobu et al., 1990) and it has been shown
to stimulate the growth of human fibro-
blasts (Ogawa et al., 1985a) and endothe-
lial cells (McKeehan et al., 1986) and rat
pancreatic cancer cells (Freeman et al.,
1990c). However, in the study of Ohmachi
et al. (1994), PSTI/TATI did not have an
effect on the growth of fibroblasts or pan-
creatic cancer cells. Furthermore, growth
stimulation of endothelial cells has also been
shown to be induced by other serine pro-
teinase inihibitors, e. g., aprotinin and ΑPI
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(McKeehan et al., 1986), suggesting that
stimulation of cell growth may be brought
about by general inhibition of proteinase
activity and possibly by inhibition of deg-
radation of other growth factors (Freeman
et al., 1990c). These observations suggest
that PSTI/TATI may have direct or indi-
rect growth promoting activity on non-neo-
plastic and neoplastic cells but its mecha-
nism of action and significance in vivo re-
mains to be clarified.
The serum levels of PSTI/TATI increase
in connection with severe inflammatory dis-
eases (Ogawa et al., 1980; Lasson et al.,
1986), tissue destruction (Ogawa et al.,
1985b) and major surgery (Matsuda et al.,
1985) which suggests that PSTI/TATI plays
a role in the acute phase reaction. Many
acute phase proteins are proteinase inhibi-
tors produced by the liver in response to
inflammatory cytokines. They are thought
to suppress nonspecific tissue damage
caused by proteinases released from acti-
vated immune and phagocytic cells (Rob-
erts et al., 1995). Being a source of acute
phase proteins, the liver is also a potential
source of PSTI/TATI. Although PSTI/TATI
mRNA has not been detected in normal
human liver tissue (Yamamoto et al., 1985)
the possibility that it originates from the
liver is supported by the finding that it is
produced in hepatoblastoma cells (Yasuda
et al., 1990) and hepatocellular cancer
(Ohmachi et al., 1993; Jönsson et al., 1996).
Furthermore, its synthesis by hepato-
blastoma cells is stimulated by IL-6 (Yasuda
et al., 1990) which is a major proin-
flammatory cytokine induced by TNF-α
and IL-1 (Roberts et al., 1995). An IL-6
responsive element (IL6RE) has been iden-
tified in the PSTI/TATI gene (Yasuda et al.,
1993). The role as well as the origin of
PSTI/TATI in acute phase reactions is pres-
ently unknown. Whereas PSTI/TATI ex-
pression in the pancreas and tumors seems
to be associated with production of trypsin,
a proteinase reacting with PSTI/TATI has
not yet been identified in inflammatory
cells (Stenman et al., 1991). However, it
has recently been shown that trypsin stimu-
lates TNF-α and IL-1 production by rat
peritoneal macrophages (Lundberg et al.,
2000) which may indicate a link between
trypsin and PSTI in the acute phase re-
sponse.
3.5 Clinical aspects
The serum and urine levels of TATI are el-
evated in patients with various types of can-
cer (reviewed by Stenman et al. 1993), e. g.,
in patients with advanced gynecological
(Huhtala et al., 1982; Stenman et al., 1982;
Halila et al., 1988; Mogensen et al., 1990),
pancreatic (Matsuda et al., 1983; Haglund
et al., 1986), and renal cancer (Meria et al.,
1995). The mechanisms causing the eleva-
tion of TATI in cancer patients may be pro-
duction of TATI by the tumor or reaction
against tissue destruction caused by inva-
sive cancer (Stenman et al., 1991). As a tu-
mor marker TATI is most useful in the man-
agement of mucinous ovarian cancer (Halila
et al., 1988) in which it complements CA
125 whereas in patients with non-mucinous
ovarian cancer it does not improve sensitiv-
ity (Mogensen et al., 1990). High serum lev-
els of TATI have been observed in patients
with stage I mucinous ovarian cancer (Halila
et al., 1988) who generally have a good prog-
nosis (Vergote et al., 1993). TATI has been
shown to be an independent prognostic
marker in advanced non-mucinous epithe-
lial ovarian cancer (Venesmaa et al., 1994;
Venesmaa et al., 1998) and in bladder can-
cer (Kelloniemi et al., unpublished).
Review of the Literature
Annukka Paju
28
Aims of the study
1) It has been shown that serum TATI lev-
els are increased in patients with renal cell
cancer but the explanation for this phenom-
enon and its usefulness in the monitoring
of the disease is lacking. Therefore we stud-
ied whether PSTI/TATI is expressed in nor-
mal and malignant renal tissue and in renal
cancer cell lines (I) and analysed the value
of TATI as a prognostic factor in renal cell
carcinoma (II).
2) Little is known about the mechanisms
which regulate the expression of trypsino-
gen. Therefore we studied the effect of
chemically modified tetracyclines and doxy-
cycline, which are inhibitors of MMP ex-
pression, on trypsinogen expression in can-
cer cells (III).
3) Human trypsin-2 activates proMMP-2
and proMMP-9 in vitro. To elucidate the role
of trypsins in the activation of proMMPs in
vivo, we studied the association of trypsino-
gen-1, trypsinogen-2, their API complexes,
and TATI with activation of proMMP-2 and
proMMP-9 in ovarian tumor cyst fluids
(IV).
4) Human seminal plasma contains several
proteinases, e. g.,  prostate-specific antigen
(PSA) and human kallikrein-2 (hK2) which
regulate sperm motility. The physiological
activators of proPSA are not known. Because
bovine trypsin activates proPSA in vitro, we
studied whether trypsinogens occur in hu-
man seminal fluid and are expressed in the
male genital tract (V).
The aim of this work was to study the expression of trypsinogens and PSTI/TATI in
normal and malignant urogenital tissues and to elucidate their role in the proteolytic
activity of tumors. The specific aims listed below were formed during the course of the
study.
29
Materials and methods
1. SAMPLES
The use of samples of human tissues and
body fluids for this study was approved by
the ethical committees of Helsinki Univer-
sity Central Hospital, Finland and Univer-
sity Hospital in Umeå and Malmö Univer-
sity Hospital, Sweden.
Serum of patients with renal cell carci-
noma (I, II) were obtained from the serum
bank of the Department of Urology and
Andrology, University Hospital in Umeå
(Table I). Control sera were obtained from
healthy laboratory personnel from Helsinki
University Central Hospital. Specimens of
normal and malignant renal tissue and pan-
creatic tissue (I) were obtained from the
Department of Pathology, the Haartman
Institute, Helsinki University Central Hos-
pital and the Department of Urology and
Andrology, University Hospital in Umeå.
Ovarian adenocarcinoma tissues were ob-
tained from the Department of Obstetrics
and Gynecology, Helsinki University Cen-
tral Hospital (IV). Tissue specimens of hu-
man prostate, seminal vesicles, ductus (vas)
deferens, epididymis, testis, and pancreas
(V) were obtained from the Department of
Surgery, Malmö University Hospital. Ova-
rian tumor cyst fluid samples (IV) were
obtained from the Department of Obstet-
rics and Gynecology, Helsinki University
Central Hospital. Seminal plasma samples
(V) were obtained from the Department of
Obstetrics and Gynecology, Helsinki Uni-
versity Central Hospital. Urine from pa-
tients with pancreatitis used for purifica-
tion of trypsinogen and PSTI/TATI (III, V)
were obtained from the Department of Sur-
gery, Helsinki University Central Hospi-
tal.
2. SPECIAL REAGENTS
The antimicrobial tetracycline, doxycycline,
and the chemically modified tetracyclines
lacking antimicrobial activity, CMT-1,
CMT-3, CMT-5 and CMT-8, were provided
by Collagenex Pharmaceuticals, Inc.,
Newtown, PA, USA. Chromogenic peptide
substrates N-benzoyl-L-isoleucyl-L-
glutamyl-glycyl-L-arginine-p-nitroanilide
(S-2222) and 3-carbomethoxy-propionyl-L-
arginyl-L-prolyl-L-tyrosine-p-nitroanilide
(S-2586) were purchased from Kabi-
Vitrum, Stockholm, Sweden. Bovine enter-
okinase (E. C. 3.4.21.9) was purchased from
Boehringer-Mannheim, Mannheim, Ger-
many. Antibodies used are listed in Table
II.
3.METHODS
The methods used are listed in Table III and
briefly described below. Details can be found
in the original publications (I-V).
3.1 Purification of trypsinogen, PSTI/
TATI, and PSA
Trypsinogen-1, trypsinogen-2 and PSTI/
TATI were purified from urine of pancre-
atitis patient and from seminal fluid by af-
finity chromatography using monoclonal
anti-trypsinogen-1 (3E8), anti-trypsinogen-
2 (14F10 and 14D4) and anti-PSTI/TATI
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(6E8) columns. Further fractionation was
performed by ion exchange (trypsinogens)
and reverse phase (PSTI/TATI) chromatog-
raphy. ProPSA was purified from LNCap
cell medium (Corey et al., 1998) and ma-
ture PSA from seminal fluid as described
(Zhang et al., 1995).
3.2 Cell culture
All cells were obtained from American
Type Culture Collection (Rockville, MD,
USA) (Table IV) and were grown at 37 °C
in a humified atmosphere with 5% CO
2
.
Human renal cancer cell lines A-498 and
ACHN were maintained in Eagle’s Mini-
mum Essential Medium supplemented
with 0.1 mM non-essential amino acids,
1.0 mM sodium pyruvate, 90% Earle’s
BSS, 10 % fetal bovine serum (FBS), 2 mM
glutamine, 100 units/ml penicillin and
100 µg/ml streptomycin. Renal cancer cell
lines 786-O, A 704, Hs 126.T, Hs 227.T,
796-P, the colon adenocarcinoma cell line
COLO 205, and the prostatic adenocarci-
noma cell line LNCap were maintained in
Table I. Samples of patients and controls.
Normal tissues of the male
genital tract
Abbreviations: RCC, renal cell carcinoma; OVCA, ovarian carcinoma; IVF, in vitro fertilization; CAP, prostate
cancer; CAB, cancer of urinary bladder; BPH, benign prostatic hyperplasia.
Tissue samples
Cyst fluids
Sample Subject n Used in
RCC patients 21 ISerum samples
RCC patients II
Healthy volunteers 84 II
Normal renal tissue RCC patients 20 I
RCC tissue RCC patients 32 I
Normal pancreatic tissue Patients with pancreatic
cancer
2 I, V
OVCA tissue Patients with mucinous
OVCA
10 IV
Patients with serous
OVCA
10 IV
Testis VPatients with CAP 6
Epididymis VPatients with CAP 6
Ductus (vas) deferens VPatients with CAP 6
VAmpulla of ductus (vas)
deferens
Patients with CAP 6
Prostate VPatients with CAP,
CAB or BPH
8
Seminal vesicles VPatients with CAP or
CAB
8
Ejaculatory duct VPatients with CAP 6
Prostatic utricle VPatients with CAP 6
Urethra Patients with CAP 6 V
Cyst fluid of ovarian tumor Patients with malignant
ovarian tumor
20 IV
Patients with benign
ovarian tumor
41 IV
Seminal plasma Men participating in an
IVF program
24 V
188
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RPMI 1640 medium supplemented with
10% heat-inactivated fetal bovine serum,
2 mM glutamine, 100 units/ml penicillin
and 100 µg/ml streptomycin. LNCap me-
dium additionally contained 0.1 mM non-
essential amino acids and 5 mM testoster-
one.
3.2.1 Cell growth assay
Proliferation of COLO 205 cells was deter-
mined using the MTT Based Cell Growth
Determination Kit (Sigma Biosciences, St.
Louis, MO, USA) according to the
manufacturer´s instructions with minor
Materials and Methods
V
Immunohistochemistry
Immunofluorometric assays
11B3 (Eu) & 6E8 TATI Osman et al., 1993 I, II, IV
Immunoaffinity chromatography
3E8 MAb anti-try-1, IgG Itkonen et al., 1990 V
Western blotting
Abbreviations: MAb, monoclonal antibody; PAb, polyclonal antibody; TATI, tumor-associated
trypsin inhibitor; try, trypsinogen; MMP, matrix metalloproteinase; API, α1-proteinase inhibitor;
PSA, prostate-specific antigen; ACT,  α1-antichymotrypsin; IgG, purif ied IgG fraction; Eu,
europium-labelled Ab
Table II. Antibodies used.
Antibody Description Source/reference Used in
EC8 MAb anti-TATI, IgG Osman et al., 1993 I, IV
7401 PAb anti-try-1, sheep serum Borgström and Ohlsson, 1976 V
3E8 MAb anti-try-1, IgG Itkonen et al., 1990 V
6D11 MAb anti-try-1, IgG Itkonen et al., 1990 V
Fahat PAb anti-try-2, sheep serum Kimland et al., 1989 V
8336 PAb anti-try-2, rabbit serum Kimland et al., 1989
8F7 MAb anti-try-2, IgG Itkonen et al., 1990 IV, V
14D4 MAb anti-try-2, IgG Itkonen et al., 1990 V
14F10 MAb anti-try-2, IgG Itkonen et al., 1990 V
MAB 1482 MAb anti-try, IgG Chemicon international,
Temecula, CA, USA
V
PAb anti-MMP-2, IgGMMP-2 Turpeenniemi-Hujanen
et al., 1992
IV
PAb anti-MMP-9, IgGMMP-9 Kjeldsen et al., 1993 IV
6D11 (Eu) & 3E8 Trypsinogen-1 Itkonen et al., 1990 IV, V
14F10 (Eu) & 14D4 Trypsinogen-2 Itkonen et al., 1990 IV, V
PAb anti-API (Eu) & 3E8 Trypsin-1-API Hedström et al., 1999 IV
PAb anti-API  (Eu)& 14F10 Trypsin-2-API Hedström et al., 1994 IV
MAb anti-ACT (Eu) & H117 PSA-ACT Leinonen et al., 1996 V
14F10 MAb anti-try-2, IgG Itkonen et al., 1990 V
14D4 MAb anti-try-2, IgG Itkonen et al., 1990 V
6C11 MAb anti-PSA, IgG Leinonen et al.,
unpublished
V
PAb anti-try, rabbit serum Koivunen et al., 1989 IV, VRabbit 13
MAb anti-try-2, IgG Itkonen et al., 1990 III14F10
PAb anti-MMP-2, IgG Turpeenniemi-Hujanen
et al., 1992
IVMMP-2
PAb anti-MMP-9, IgG Kjeldsen et al., 1993 III, IVMMP-9
6E8 Mab anti-PSTI/TATI, IgG Osman et al., 1993 III, V
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modifications. Briefly, cells were removed
in PBS by a cell scraper and MTT solution
was added.  The dye metabolized by the cells
was dissolved and the absorbance was read
at 564-690 nm on a microplate reader
(Labsystems Multiskan R Bichromatic,
Labsystems, Helsinki, Finland).
3.2.2 In vitro cell migration assay
The in vitro migration of COLO 205 cells
was measured using Transwell migration
chambers (Corning Costar Corporation,
Cambridge, MA, USA) coated with 10 µg/
ml laminin from human placenta (Sigma).
COLO 205 cells were seeded in the com-
plete serum-containing medium in the pres-
ence or absence of enterokinase, TATI,
CMTs, or DOXY into the upper wells of
the chamber. After culture for 24 h, the
number of cells that had migrated to the
bottom of the lower wells were counted
microscopically.
3.3 RNA and DNA methods
3.3.1 RNA isolation
Total RNA was extracted from exponen-
tially growing cultured cells and from fresh
tissue specimens according to the method
of Chomczynski and Sacchi (1987) using
Heavy Phase Lock Gel tubes (5 Prime-> 3
Prime, Inc., Boulder, CO, USA).
3.3.2 RT-PCR
One µg of total RNA was transcribed into
cDNA using SuperScriptTM II –reverse tran-
Cell line Description Source Used in
Abbreviation: ATCC, American Type Culture Collection
Table IV. Cell lines used.
A-498 Renal cancer, epithelial ATCC I
ACHN Renal cancer, epithelial ATCC I
786-O Renal cancer, epithelial ATCC I
A 704 Renal cancer, epithelial ATCC I
Hs 126.T Renal cancer, epithelial ATCC I
Hs 227.T Renal cancer, fibroblast ATCC I
796-P Renal cancer, fibroblast ATCC I
COLO 205 Colon adenocarcinoma ATCC III
LNCap Prostate adenocarcinoma ATCC V
Method Used in
In situ hybridization I, V
Northern blotting V
III, IV
Table III.  Methods used in this study.
RNA and DNA methods
Immunological methods
Statistical analyses II, III, IV
Protein purification III, V
Cell culture I, III, V
Cell growth assay III
In vitro cell migration assay III
RNA isolation I, III, V
RT-PCR I, III, V
Cloning I, V
Sequencing of DNA III, V
Southern blotting I, III
I, II, III, IV, V
Immunohistochemistry I, IV, V
Western blotting
Zymography
Time-resolved immuno-
fluorometric assay (IFMA)
III, IV, V
Measurement of enzyme activity III, V
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scriptase (Gibco BRL, Paisley, Scotland) ac-
cording to the manufacturer’s instructions.
Contamination of RNA samples with
cDNA was excluded with control reactions
without RT. One µl of reverse transcription
product was amplified in a 40-µl reaction
volume in 1 X PCR buffer (10 mM Tris-
HCl, pH 8.8, 1.5 mM MgCl
2
, 50 mM KCl,
0.1 % Triton X-100; Finnzymes, Espoo,
Finland), 0.25 mM of each dNTP, 20 pmol
of antisense and sense primers, and 1.6 U of
Dynazyme DNA polymerase (Finnzymes).
The primers and amplification conditions
for PSTI/TATI are found in publication I
and those for trypsinogens in publications
III and V. The RT-PCR products were sepa-
rated in a 1.5% agarose gel and stained with
ethidium bromide. The intensities of the
PCR bands were estimated with a UMAX
Powerlook II digital scanner (UMAX Tech-
nologies, Inc., Fremont, CA, USA) using the
NIH Image program for Macintosh (III).
3.3.3 Cloning of RT-PCR products
PSTI/TATI and trypsinogen cDNAs pre-
pared by RT-PCR from COLO 205 total
RNA were cloned using the TA Cloning
Kit (Invitrogen, San Diego, CA, USA) to
generate templates for in situ hybridization
riboprobe synthesis.
3.3.4 DNA sequencing
The identity of RT-PCR products and the
sequence of the templates used for in situ
hybridization riboprobe synthesis was con-
firmed by sequencing using an ABI PrismTM
Dye Terminator Cycle Sequencing Core Kit
with AmpliTaq DNA Polymerase and the
ABI Prism 310 Genetic Analyser (PE
Biosystems, Foster City, CA, USA).
3.3.5 In situ hybridzation
In vitro transcriptions of digoxigenin-labeled
sense and antisense probes for PSTI/TATI
(I) were done using the DIG RNA-labeling
kit (Boehringer-Mannheim) and a 243-bp
long PSTI/TATI cDNA fragment as a tem-
plate. Fluorescein-labeled trypsinogen
probes (V) were prepared by fluorescein-
UTP riboprobe synthesis using the RNA
color kit (Amersham Pharmacia Biotech,
Uppsala, Sweden) and a 627-bp long trypsi-
nogen-2 cDNA fragment as a template. In
situ hybridization was performed on 4- or
5-µm tissue sections which were deparaf-
finized, treated with proteinase K and fixed
in 4% paraformaldehyde. Sections were cov-
ered with hybridization buffer containing
200 or 250 ng/ml antisense or sense probe.
After overnight incubation at 42 °C or 55
°C in a humified chamber, the slides were
washed at stringent conditions. The
digoxigenin-labeled probe for PSTI/TATI
was detected using anti-digoxigenin-alka-
line phosphatase Fab fragments (Boehringer-
Mannheim) and Fast Red tablets. Fluores-
cein-labeled probe for trypsinogen was de-
tected using anti-fluorescein-alkaline phos-
phatase conjugate (Amersham Pharmacia
Biotech), nitroblue tetrazolium chloride
(NBT) and 5-bromo-4-chloro-3-indolyl
phosphate (BCIP). Pancreatic tissue was
used as a positive control in each experiment.
3.3.6 Northern blotting
Nylon membrane blotted with 2 µg of poly
A RNA (Clontech Laboratories, Inc., Palo
Alto, CA, USA) was hybridized with a 627-
bp long 32P-labeled trypsinogen-2 cDNA.
The 32P-cDNA-mRNA hybrids were visu-
alized by autoradiography. A glyceralde-
hyde-3-posphate dehydrogenase (GAPDH)
cDNA probe was used to quantify the
amount and control the quality of loaded
poly A RNA.
3.3.7 Southern blotting
Aliquots of the RT-PCR products were sepa-
rated in 1.5% agarose gel, stained with
ethidium bromide and blotted onto nylon
membranes. The membranes were hybrid-
Materials and Methods
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ized with 20-bp (PSTI/TATI) and 25-bp
(trypsinogen-2) long 32P-labeled cDNA
probes. The 32P-cDNA-cDNA hybrids were
visualized by autoradiography.
3.4 Immunological methods
3.4.1 Time-resolved immunofluorometric assay
(IFMA)
Immunofluorometric assays for TATI
(Osman et al., 1993), trypsinogen-1
(Itkonen et al., 1990), trypsinogen-2
(Itkonen et al., 1990), trypsin-1-API
(Hedström et al., 1999), trypsin-2-API
(Hedström et al., 1994), and PSA-ACT
(Leinonen et al., 1996) were based on mono-
clonal catcher antibodies and europium (Eu)
labeled monoclonal or polyclonal tracer an-
tibodies as shown in Table II. The assays
were performed in microtitration plates in
two steps. Twenty-five µl of sample and 200
µl of assay buffer were pipetted into the
wells. After incubation, the wells were emp-
tied, washed, and filled with 200 µl of as-
say buffer containing 50 ng of Eu-labeled
antibody. After incubation and washing,
200 µl of enhancement solution was added
and the fluorescence was measured in a 1234
DELFIA research fluorometer (Wallac,
Turku, Finland). When necessary, an in-
crease in detection sensitivity was achieved
by using a sample volume of 200 µl or by
concentrating the samples with Centricon-
3 concentrators (Amicon Inc., Beverly, MA,
USA). The concentration of PSA was deter-
mined by the Delfia EQM PSA kit (Wallac,
Turku, Finland) which recognizes free PSA
and total PSA equally.
3.4.2 Immunohistochemistry
Immunohistochemistry was performed on
paraffin-embedded tissues sections using
immunoperoxidase staining with the
Vectastain Elite ABC Kit (Vector Labora-
tories Inc., Burlingame, CA, USA) for
TATI, trypsinogen-2, MMP-2, and MMP-
9 (I, IV) and DAKO ChemMate™ Detec-
tion Kit and a staining machine (DAKO
TechMate™ 500/1000, BioTek Solutions,
USA) for trypsinogen-1 and –2 (V). The
primary antibodies used are listed in Table
II. The  tissue sections were deparaffinized
and rehydrated after which they were treated
with 0.5% hydrogen peroxide to quench
endogenous peroxidase activity. To enhance
antigen retrieval, the tissue sections were
pretreated either with pepsin, trypsin or
with microwave heat depending on the an-
tibody. Non-specific staining was blocked
by treatment with normal serum. The sec-
tions were first incubated with primary and
after washing with secondary antibodies.
Bound antigen-antibody complexes were
visualised by the avidin-biotin complex
immunoperoxidase technique (ABC) (Elite
ABC Kit) (I, IV) or with peroxidase/3-
amino-9-ethylcarbazole reagent of the
ChemMate kit (V). For each tissue section,
a negative control was stained by replacing
the monoclonal and polyclonal primary an-
tibodies with non-immune mouse or rab-
bit IgGs, respectively. Pancreatic tissue was
used as a positive control.
3.4.3 Western blotting
Cell culture medium, cyst fluid, or puri-
fied protein samples were separated by SDS-
polyacrylamide gel electrophoresis on 7.5%
or 3-16% gels under non-reducing or re-
ducing conditions and transferred to nitro-
cellulose filters electrophoretically. The fil-
ters were incubated with polyclonal or
monoclonal antibodies against trypsinogen,
MMP-2, or MMP-9 as listed in Table II.
The antigen-antibody complexes were vi-
sualized with peroxidase-conjugated sec-
ondary antibodies and diaminobenzidine
tetrahydrochloride.
3.5 Zymography
Cell culture medium or cyst fluid samples
were run under non-reducing conditions on
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7.5-10% gradient SDS-polyacrylamide gels
impregnated with 1 mg/ml gelatin. After
washing, the gels were incubated in 50 mM
Tris-HCl, pH 7.8, containing 150 mM
NaCl, 1 mM CaCl
2
, 1 µM ZnCl
2
, and 0.02%
NaN
3
 for 48 h at 37 °C and stained with
Coomassie Brilliant Blue. The total MMP
content and the proportions of proforms and
active forms of MMP-2 and MMP-9 were
estimated with the Bio-Rad Model GS-700
Imaging Densitometer using the Molecu-
lar AnalystTM/PC program.
3.6 Measurement of enzyme activity
3.6.1 Measurement of trypsin-2 activity
The activity of trypsin-2 preincubated in
the presence or absence of CMTs, DOXY
or TATI was determined by using β-casein
as a substrate essentially as described (Sorsa
et al., 1997) or by using  a chromogenic
peptide S-2222 as a substrate and by mea-
suring the absorbance at 405 nm on a
microplate reader (III). The activity of
trypsinogen fractions purified by immuno-
affinity and anion exchange chromatogra-
phy from seminal fluid were determined
using S-2222 as a substrate (V).
3.6.2 Measurement of proPSA activation
Activation of proPSA purified from LNCap
cell medium by trypsin-1 and trypsin-2
purified from seminal fluid was measured
by analysing the formation of PSA-α
1
-
antichymotrypsin complex (PSA-ACT) us-
ing PSA and PSA-ACT immunoassays (V).
Activation of recombinant proPSA
(kindly provided by Dr. Janita Lövgren,
University of Turku, Finland) by pancre-
atic trypsin-2 was studied using S-2586 as
a substrate and monitoring the absorbance
at 405 nm on a microplate reader.
3.7 Statistical analyses
The Mann-Whitney U test was used to
compare the differences between groups (II,
III, IV). The survival curves were con-
structed using the Kaplan-Meier method,
and comparison of survival times was per-
formed with the log-rank test (II). The in-
dependence of various factors as predictors
of survival was analysed by the stratified log-
rank test (II). All tests were two-sided and
the significance level was set to a p-value ≤
0.05.
Materials and Methods
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Results and discussion
1. EXPRESSION AND PROGNOSTIC
VALUE OF TATI IN RENAL CELL
CARCINOMA (I, II)
Renal cell carcinoma (RCC), which origi-
nates from the epitelium of the renal pa-
renchyma, is the third most common geni-
tourinary tumor, accounting for more than
2% of cancer incidence in the United States
and an estimated 12 000 deaths in 1998
(Tsui et al., 2000). There are currently no
clinically useful serum markers for this dis-
ease. According to several studies, the se-
rum levels of TATI are elevated in patients
with RCC and the clinical sensitivity of
TATI has been found to be between 37%
and 69% (Larbre et al., 1990; Taccone et al.,
1991; Meria et al., 1995). The specificity of
TATI is rather low (65%) rendering it un-
suitable for primary diagnostics, but Meria
et al. (1995) suggested that it may be use-
ful for post-operative follow-up. It has been
unclear whether the increase of serum TATI
in patients with RCC is caused by an acute
phase reaction frequently associated with
cancer, impaired renal function, or by pro-
duction of TATI by malignant and benign
renal tissue. To answer this question, we
studied the expression of TATI in histologi-
cally normal and malignant renal tissue and
in seven RCC cell lines by immunohis-
tochemistry, RT-PCR, in situ hybridization,
and IFMA. TATI concentrations were also
determined in serum of 21 RCC patients
by IFMA (I). By immunohistochemistry,
TATI was detected in the histologically
normal renal tissue in which it localized to
the distal convoluted tubules whereas the
glomeruli and proximal tubules were nega-
tive. TATI was not detected in RCC tissue
by immunohistochemistry, but by RT-PCR
TATI transcripts were detected both in nor-
mal and malignant renal tissue. However,
TATI mRNA was not detectable by in situ
hybridization in either tissue under condi-
tions in which PSTI/TATI mRNA was dem-
onstrated in the acini of the normal pan-
creas. RT-PCR and IFMA showed that TATI
mRNA and protein were expressed also by
RCC cell lines (Table V). The serum con-
centrations of TATI were elevated in 57%
of all RCC patients. Only one patient had a
clearly elevated serum creatinine indicating
impared renal function, which could explain
the TATI  elevation in that patient.
Expression of PSTI/TATI in the kidney
has earlier been studied by Fukayama et al.
(1986) and by Marchbank et al. (1996), who
detected PSTI/TATI mRNA and protein
expression in the transitional epithelium of
the renal pelvis. In the study of Fukyama et
al. PSTI/TATI immunoreactivity was also
MorphologyCell line
Table V. Expression of TATI protein and mRNA in renal
cancer cell lines.
Abbreviation: ND, not determined
TATI (ng/l) TATI RT-PCR
Epithelial  7.7 +A-498
Epithelial  ND +ACHN
Epithelial  10.0 +786-O
Epithelial  1.8 +A 704
Fibroblast  1.5 +769-P
Epithelial   -
-
Hs 126.T
Fibroblast  - +Hs 227.T
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detected in the collecting ducts of the fetal
kidney. However, the staining in the fetal
collecting ducts decreased with increasing
gestational age, until no staining was ob-
served in the adult kidney. The authors sug-
gested that this phenomenon might reflect
differentiation of the collecting ducts.
Marchbank et al. detected PSTI/TATI pep-
tide, but not mRNA in the collecting ducts
of adult kidney suggesting renal reabsorp-
tion of the filtered peptide by the tubules.
This observation differs from our findings.
We detected TATI immunoreactivity in the
distal tubules which do not participate in
protein reabsorption (I). Because TATI
mRNA also was detected by RT-PCR, this
suggests that TATI is expressed by tubular
cells. A rapid turnover of TATI mRNA may
explain why we failed to detect TATI tran-
scripts in renal tissue by in situ hybridiza-
tion. The negative result of the immuno-
histochemical staining of malignant renal
tissue may, on the other hand,  be caused
by rapid leakage or secretion of TATI, prob-
ably produced at low levels, into circula-
tion.
In RCC, the extent of tumor spread
(stage) and nuclear grade are considered to
be the main prognostic factors (Fuhrman et
al., 1982; Medeiros et al., 1988). However,
in subsets of patients within a given dis-
ease stage, there are large variations in the
clinical course and survival time. Therefore,
there is a need for prognostic factors that
could identify patients with an aggressive
disease. Although there are no specific se-
rum markers for RCC, some general mark-
ers, e. g., CA-125 (Grankvist et al., 1997),
tumor necrosis factor-α (Dosquet et al.,
1997), interleukin-10 (Wittke et al., 1999),
and neuron-specific enolase (Rasmuson et
al., 1999) provide some prognostic infor-
mation.
We studied the prognostic value of pre-
operative serum TATI in relation to stage
and grade in 158 patients with RCC and a
normal serum creatinine (II). Elevated pre-
operative serum TATI levels (cut-off 16 µg/
l) were  detected in 48% of the RCC pa-
tients (in 39% of those with stage I or II
and in 56% of those with stage III or IV
tumors) (Table VI). The concentration of
TATI in cancer patients (median 15 µg/l)
was significantly higher than in controls
(median 11 µg/l) (p < 0.0001). Serum TATI
correlated with clinical stage and nuclear
grade (Table VI). In univariate analysis, sur-
vival was strongly associated with clinical
stage and nuclear grade (p < 0.0001), and
patients with elevated TATI levels had sig-
nificantly shorter survival time than those
with normal TATI levels (p = 0.005) (Fig-
Results and Discussion
Cases Range
Stage
TATI (µg/l)
Grade
Table VI. Serum TATI concentration in relation to grade and stage of the tumor.
Elevated (%) Median Inter-quartile
range
*Mann-Whitney U test p = 0.5 and 0.01 versus III and IV, respectively.
**Mann-Whitney U test p = 0.06 and 0.003 versus III and IV, respectively.
70I, II 27 (39%) 13.8*6.2-493 11.1-21.0
41III 22 (54%) 17.08.2-155 10.2-39.5
47IV 27 (57%) 22.46.1-1140 12.2-38.1
401, 2 15 (38%) 13.1**8.5-493 9.9-20.4
803 37 (46%) 14.18.5-1440 11.1-24.5
384 24 (63%) 23.26.2-1140 11.7-67.2
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ure 1, Table VII). In a stratified log-rank
test, TATI was a prognostic factor indepen-
dent of stage (p = 0.03) and grade (p ≤ 0.04)
among all patients and also among those
with non-metastatic disease.
TATI is cleared from the circulation by
renal excretion and is partially reabsorbed
by the renal tubules. Thus serum TATI in-
creases in patients with markedly impaired
renal function (Tramonti et al., 1996). El-
evated serum concentrations of creatinine
indicate impaired renal function, and pa-
tients with serum creatinine above 125
µmol/l were therefore excluded from the
analysis. In the study of Meria et al. (1995),
the sensitivity of TATI was 69%, which is
higher than in our studies (57%, study I
and 48%, study II). Exclusion of patients
with elevated serum creatinine from our
analysis may explain the difference.
It is seemingly paradoxical that a high
concentration of TATI, an inhibitor of
trypsin, is associated with poor prognosis.
Trypsinogen mRNA and protein are ex-
pressed in the kidney (Koshikawa et al.,
1998), and it is possible that, like in the
pancreas, the role of TATI in some tumors
is to inhibit intracellular trypsin activity
and hence protect the tissue producing it.
TATI cut-off (µg/l)
Table VII. Univariate analysis of variables predicting
survival by the log-rank test.
All stages Stage IVStages I-III
16.0  0.005 0.180.02
30.0-50.0 < 0.0005 <0.004<0.006
Grade < 0.0001
Stage < 0.0001
2. ASSOCIATION OF TRYPSINO-
GEN EXPRESSION IN TUMOR
CELLS WITH ACTIVATION OF
PROMMP-2 AND -9 AND WITH
CELL MIGRATION (III, IV)
Tetracyclines are broad-spectrum antibiot-
ics which act by blocking bacterial protein
synthesis. Golub et al. (1983) found that
they are also anti-collagenolytic, an effect
which is unrelated to their antibacterial
properties and possibly of therapeutical
importance per se. In order to prevent side
effects caused by emergence of antibiotic-
resistant micro-organisms, chemically
modified tetracyclines (CMT) lacking an-
timicrobial activity have been developed
(Golub et al., 1987). Both tetracyclines and
Time (months)
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Figure 1. Kaplan-Meier cancer specific survival according  to preperative TATI concentration in patients with RCC.
A, all stages. B, stages I-III. Cut-off 16 µg/l.
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CMTs are capable of inhibiting MMP ac-
tivity and expression (Golub et al., 1983;
Golub et al., 1987; Uitto et al., 1994) and
are therefore potential therapeutic agents for
treatment of cancer. The inhibition of MMP
activity has been suggested to be dependent
on the ability of tetracyclines to chelate Ca2+
and Zn2+ ions (Golub et al., 1983). This is
supported by the finding that CMT-5,
which lacks the β-diketone moiety at car-
bon-11 and carbon-12 required for chelat-
ing of multivalent metal cations, does not
inhibit MMP activity (Sorsa et al., 1998)
(Figure 2). The mechanism by which tetra-
cyclines and CMTs inhibit MMP expression
(Uitto et al., 1994; Jonat et al., 1996;
Hanemaaijer et al., 1998) is not clear. Tet-
racyclines inhibit protein kinase C activity
(Webster et al., 1994) which plays a pivotal
role in the transcriptional activation of cer-
tain MMP genes (Case et al., 1990;
Takahashi et al., 1993). Protein kinase C is
part of a signal pathway comprising to the
AP-1 complex, which is supposed to be a
transcription-stimulating factor binding to
the MMP promoter (Angel et al., 1987).
4-Dedimethylamino tetracycline
CMT-1
4-Dedimethylamino sancycline
CMT-3
Tetracycline pyrazole
CMT-5
4-Dedimethylamino doxycycline
CMT-8
Tetracycline Doxycycline
*
OH
OH
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OOOH
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2
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*OH
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Figure 2. Chemical structures of tetracycline, doxycycline, and the chemically modified tetracyclines (CMTs). The
carbonyl group at C11 and the OH group at C12 which form the Ca
++
 and Zn++ binding site in the molecules
excluding CMT-5 are marked with * in tetracycline.
N(CH3)2
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However, Jonat et al. (1996) suggested that
the transcriptional inhibition of stromelysin
by tetracycline is not due to a blocking of
the activity of AP-1 but is mediated by yet
unidentified sequences upstream of the AP-
1 binding site in the stromelysin gene.
We aimed at investigating whether the
synthetic tetracycline doxycycline and
CMTs affect trypsinogen-2 expression and
activity (III). We found that DOXY and
several CMTs (CMT-1, -3, 5, and -8)
downregulated the expression of trypsino-
gen-2 in COLO 205 colon adenocarcinoma
cells by 20-70% at non-cytotoxic concen-
trations (0.1 to 1 µM) (Figure 3). The
mechanism causing the inhibition of trypsi-
nogen-2 expression remains to be eluci-
dated. Trypsin-2 activity was not affected
by doxycycline or CMTs. This is in line with
the fact that the catalytic activity of trypsin
is not dependent of divalent cations. Al-
though Ca2+ is essential in stabilazing
trypsin and the absence of Ca2+ causes rapid
autolysis of especially trypsin-2 (Colomb et
al., 1978), it is likely that the CMT and
DOXY concentrations used in the inhibi-
tion experiments (50 µM) were not high
enough to cause Ca2+ deprivation and sub-
sequent autodegradation and loss of activ-
ity of trypsin-2.
The role of trypsin in cancer cell migra-
tion was studied using DOXY and CMTs
together with enterokinase and TATI. By
zymography we first found that addition of
enterokinase to the cell culture medium
enhanced proMMP-9 activation. This effect
was inhibited by TATI and DOXY, but not
by CMTs. Furthermore, DOXY and CMTs
showed no detectable effect on MMP-9 ex-
pression which may be explained by the use
of concentrations lower than those gener-
ally used to inhibit MMPs (Uitto et al.,
1994; Hanemaaijer et al., 1997; Seftor et al.,
1998; Gu et al., 2001). We also found that,
when added to the cell culture, enteroki-
nase enhanced migration of COLO 205 cells
and TATI abolished this effect (Figure 4).
DOXY was most effective in inhibiting the
migration of enterokinase-treated cells,
which could be explained by simultaneous
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Figure 3.  Effects of CMTs and DOXY on the release of trypsinogen-2 protein into culture
medium of COLO 205 cells. A, Cells were cultured in the presence or absence of 1 µM CMT-1, CMT-3, CMT-5, CMT-
8, or DOXY. B, Cells were cultured in the presence or absence of 0.1, 1.0, and 30 µM CMT-3. After 48 h, trypsinogen-
2 immunoreactivity was measured by an immunofluorometric assay. Trypsinogen-2 concentrations were corrected for
the cell number determined using a cell proliferation assay based on the activity of mitochondrial dehydrogenases.
The results represent mean values and standard deviations from 4 (A) and 6 (B) parallel wells. * p < 0.03, **p < 0.005,
Mann-Whitney U test.
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inhibition by DOXY of trypsinogen-2 ex-
pression and proMMP-9 activation. CMT-
3 and CMT-5, which only affected trypsi-
nogen-2 expression, but not enterokinase-
induced proMMP-9 activation, inhibited
migration of enterokinase-treated cells to a
lesser extent than TATI and DOXY. Our
results are in line with earlier studies show-
ing that tetracyclines and CMTs inhibit
migration of cancer cells (Fife and Sledge,
1995; Seftor et al., 1998; Lokeshwar, 1999)
and they further show that part of this ef-
fect may be mediated by trypsin inhibition.
The ability of TATI to inhibit COLO 205
cell migration induced by enterokinase fur-
ther supports the notion that trypsin plays
a role in cell migration. However, general
conclusions can not be drawn on the basis
of these results because only one cell line
was studied.
At the concentrations used, up to 100
µM, CMTs and DOXY were not cytotoxic.
On the contrary, culture of the cells in the
presence of 1 µM DOXY or CMTs resulted
in a 2- to 4-fold increase in cell number.
CMT-3 and CMT-8 have been reported to
decrease the proliferation of keratinocytes
(Mäkelä et al., 1998) and CMT-3 and
DOXY to cause death of cultured mono-
cytes and macrophages but not fibroblasts
possibly by an apoptotic mechanism
(Bettany and Wolowacz, 1998). In the study
of Seftor et al. (1998), on the other hand,
CMT-3 and CMT-8 caused proliferation of
human melanoma cells. The effect of CMTs
and DOXY on cell proliferation may be
specific to certain cell lines and dependent
on the CMT concentrations used. The in-
creased cell proliferation may also be caused
by suppression of general protease activity
(McKeehan et al., 1986; Freeman et al.,
1990c). This is supported by our finding
that TATI also enhanced cell proliferation
whereas enterokinase decreased it (III).
Epithelial ovarian cancers arising from the
germinal epithelium constitute 80-90% of
all malignant ovarian tumors. Of these, se-
rous cystadenocarcinomas constitute 60-
70% and mucinous cystadenocarcinomas
10-20%. Trypsinogen (Hirahara et al., 1995;
Hirahara et al., 1998), TATI (Huhtala et al.,
1982; Ueda et al., 1989), MMP-2 and MMP-
9 (Autio-Harmainen et al., 1993; Naylor et
al., 1994) are expressed in ovarian cancer
and they are found at high concentrations
in tumor cyst fluids (Koivunen et al., 1990;
Furuya et al., 2000). A recent study has
shown that human trypsin-2 activates
proMMP-2 and proMMP-9 in vitro (Sorsa et
al., 1997). Therefore we wanted to eluci-
date the role of trypsin in the activation of
proMMP-2 and -9 in vivo by comparing the
concentrations of trypsinogen-1 and -2, their
α
1
-protease inhibitor (API) complexes, and
TATI in ovarian tumor cyst fluids with the
degree of activation of proMMP-2 and -9.
We furthermore studied the immunohis-
tochemical expression and localization of
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trypsinogen-2, TATI, MMP-2, and MMP-
9 in ovarian tumors. We found that the pro-
portion of active MMP-9 was significantly
greater in cyst fluids with high (≥ 87 µg/l)
than in those with low trypsinogen-2 con-
centrations (p = 0.05). The proportion of
active MMP-9 was also greater in cyst flu-
ids with trypsin-1-API and trypsin-2-API
concentrations higher than their median
concentrations (≥ 12 and 42 µg/l, respec-
tively) (p = 0.4 and 0.1, respectively). The
differences were statistically significant at
cut-off levels of 30 µg/l (trypsin-1-API) and
100 µg/l (trypsin-2-API) (p = 0.003 and
0.03, respectively) (Figure 5A). Contrary to
MMP-9, the activation of MMP-2 was in-
versely associated with the concentrations
of trypsinogen-1, trypsinogen-2, trypsin-2-
API, and TATI. The proportion of active
MMP-2 was smaller when trypsinogen-1
and trypsin-2-API concentrations exceeded
their median concentrations (20 and 42 µg/
l, respectively) (p = 0.02). Similarly, less
active MMP-2 occured in cyst fluids with
trypsinogen-2 and TATI concentrations
above their median concentrations (87 and
25 µg/l, respectively) (p = 0.1 and 0.2, re-
spectively). The results were statistically sig-
nificant when cut-off concentrations of 50
µg/l (for trypsinogen-2) and 1000 µg/l (for
TATI) were used (p = 0.01 and 0.04, re-
spectively) (Figure 5B).
These results suggest that trypsin-1 and
trypsin-2 are involved in the activation of
proMMP-9 but not proMMP-2 in vivo.
Trypsin-2 activates proMMP-2 to a 65 kDa
species in vitro (Sorsa et al., 1997) but after
prolonged incubation further fragmentation
to a 40 kDa species occures. The N-termi-
nal amino acid sequence of the 40 kDa prod-
uct was the same as that of the 65 kDa form,
indicating additional trypsin-2-mediated
processing in the C-terminal region (Sorsa
et al., 1997). It is possible that high con-
centrations of trypsin, a very efficient pro-
teinase, may result in inactivation of MMP-
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2 or its activator MMP-14 in vivo.
We found that the concentrations of
trypsinogen-1 and trypsinogen-2 were sig-
nificantly higher in malignant than in be-
nign cyst fluids (Figure 6). This is in line
with the results of Koivunen et al. (1990).
In addition, the concentrations of trypsin-
API complexes, which reflect the propor-
tion of active trypsin, were significantly
higher in malignant than in benign fluids.
Interestingly, the molar ratio of trypsino-
gen to TATI was significantly higher in se-
rous than in mucinous cyst fluids (Figure
7). The excess of protease in relation to its
inhibitor may be related to the poorer prog-
nosis of serous than of mucinous ovarian
carcinomas (Vergote et al., 1993).
By immunohistochemistry, we detected
trypsinogen-2 and TATI in the secretory
epithelium of ovarian carcinomas as has been
earlier described (Ueda et al., 1989; Hira-
hara et al., 1995; Hirahara et al., 1998).
Trypsinogen-2 and TATI were detected
more frequently in mucinous than in serous
tumors and in agreement with this, the
trypsinogen and TATI concentrations were
significantly higher in mucinous than in
serous cyst fluids. In ovarian carcinomas,
MMP-2 mRNA expression has been de-
tected mainly in stromal fibroblasts and
endothelial cells but only rarely in epithe-
lial cells (Autio-Harmainen et al., 1993;
Naylor et al., 1994; Afzal et al., 1998)
whereas immunoreactive MMP-2 has
mainly been detected in the cytoplasm and
at the surface of epithelial tumor cells
(Autio-Harmainen et al., 1993; Höyhtyä et
.01
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al., 1994; Afzal et al., 1996; De Nictolis et
al., 1996). Several cultured ovarian carci-
noma cells produce MMP-2 and MMP-9
(Moser et al., 1994; Fishman et al., 1997;
Westerlund et al., 1997; Boyd and Balkwill,
1999). In agreement with earlier studies
(Autio-Harmainen et al., 1993; Höyhtyä et
al., 1994; Afzal et al., 1996; De Nictolis et
al., 1996) we found by immunohistochem-
istry that MMP-2 localized to the vascular
endothelial, epithelial, and stromal cells.
Furthermore, in line with several studies
suggesting stromal macrophages and tu-
mor-infiltrating neutrophils as major
sources of MMP-9 in invasive cancers, e. g.,
in the colon (Pyke et al., 1993; Nielsen et
al., 1996), bladder (Davies et al., 1993a),
and breast cancer (Davies et al., 1993b) and
ovarian carcinoma (Naylor et al., 1994), we
detected MMP-9 immunoreactivity in neu-
trophils and monocyte-macrophage-like
cells both in stromal and epithelial areas.
This is in contrast to the findings of Huang
et al. (2000), who recently demonstrated
MMP-9 mRNA and protein both in stro-
mal and neoplastic cells of ovarian carcino-
mas. MMP-9 expression has also been de-
tected in squamous cell carcinoma cells of
the lung (Canete-Soler et al., 1994), vulva
(Johansson et al., 1999), and esophagus
(Ohashi et al., 2000). The immunohis-
tochemical findings support the notion that
stromal cells, inflammatory cells, and can-
cer cells co-operatively produce and induce
tissue-destructive serine proteinases and
MMPs that facilitate tumor invasion and
metastatic spread (Pyke et al., 1993).
3. EXPRESSION AND CHARACTER-
IZATION OF TRYPSINOGENS
PRODUCED IN THE MALE GENI-
TAL TRACT (V)
Human semen consists primarily of the se-
cretions of the accessory genital glands in-
cluding the prostate, seminal vesicles, and
Cowper’s glands. It contains several pro-
teolytic enzymes such as human kallikrein-
2 (hK2) (Deperthes et al., 1995) and pros-
tate-specific antigen (PSA) (Wang et al.,
1979). PSA is a chymotrypsin-like serine
proteinase (Lilja, 1985), whereas hK2 has
trypsin-like enzymatic activity (Clements,
1994). Recent studies have shown that a
recombinant proform of PSA is activated
by bovine trypsin and recombinant hK2
(Lövgren et al., 1997; Takayama et al.,
1997), but the physiological activators of
proPSA and prohK2 are not known. It is
likely that they are activated by an enzyme
with trypsin-like specificity, since the cleav-
age of the activation peptide occurs at the
carboxyterminal side of an arginine
(Lövgren et al., 1997). Therefore, it was of
interest to find out whether trypsin is
present in human seminal fluid.
By an immunofluorometric assay we
found that trypsinogen-1 and -2 are present
at high concentrations (medians 0.4 and 0.5
mg/l, respectively) in human seminal fluid.
We purified both isoenzymes to homoge-
neity by immunoaffinity and anion ex-
change chromatography (Figure 8). The size
of the purified trypsinogen isoenzymes was
25-28 kDa as indicated by SDS-PAGE and
Western blotting. Most of the trypsinogen-
1 purified from seminal fluid was enzymati-
cally active whereas trypsinogen-2 occured
as the proform, which could be activated
by enterokinase in vitro. In addition, nicked
forms of both isoenzymes were detected by
Western blotting. These were enzymatically
inactive and could be separated by ion ex-
change chromatography from trypsinogen
and active trypsin.
To study the origin of trypsins found in
seminal plasma, we performed immunohis-
tochemical analysis of the various tissues of
the male genital tract. Trypsinogen protein
was detected in the human testis, epididy-
mal glands, deferent duct, seminal vesicles,
prostate, the ejaculatory duct, urethra, and
prostatic utricle. Expression of trypsinogen
mRNA in the same organs was further dem-
45
onstrated by in situ hybridization. Trypsi-
nogen mRNA was also detected in the pros-
tate and seminal vesicles by RT-PCR and
Northern blotting. Sequencing of the RT-
PCR products revealed that trypsinogen-1
and -2 expressed in the prostate and trypsi-
nogen-1 expressed in seminal vesicles were
encoded by the same genes as the corre-
sponding pancreatic ones.
To investigate the function of trypsin in
the male genital tract, we studied whether
it can activate the proform of PSA, and
whether its activity is affected by Zn2+ ions
present at high concentrations in the pros-
tate and seminal plasma (Kavanagh, 1985).
We found that trypsin isolated from semi-
nal plasma activated proPSA isolated from
LNCap cells (Figure 9A). This result was
confirmed by activation experiments using
human pancreatic trypsin-2 and recombi-
nant proPSA (kindly provided by Dr. Janita
Lövgren, University of Turku, Finland) (Fig-
ure 9B). Zn2+ inhibited trypsin-2 activity
in a dose-dependent manner. However, the
inhibition of trypsin was less efficient than
that of hK2:  100 µM Zn2+ inhibited hK2
activity by 90% (Lövgren et al., 1999)
whereas trypsin activity was inhibited only
by 18% (V).
This is the first study to show that trypsi-
nogens occur at high concentrations in semi-
nal plasma, and that they appear to be de-
rived from the auxiliary sex glands as evi-
denced by immunostaining. In situ hybrid-
ization and RT-PCR analysis confirmed that
this was due to local production rather than
to uptake. The widespread distribution of
trypsinogen in the male genital tract sug-
gests that this proteinase may play a physio-
logical role in reproduction. It is tempting
to speculate that this function is related to
activation of other proteinases like PSA and
hK2 that are present in seminal plasma at
high concentrations. The main function of
PSA is thought to be the dissolution of the
sperm-entrapping gel formed immediately
after ejaculation by cleavage of the gel form-
ing proteins semenogelin I and II (Lilja,
1985). It is likely that an enzyme with
trypsin-like specificity activates proPSA and
prohK2. Indeed, we found that human
trypsin activates proPSA. HK2, another po-
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tential physiological activator of proPSA
(Lövgren et al., 1997), occurs in seminal
plasma at an avarage concentration of 6 µg/
ml, which is about six times higher than that
of trypsin. However, Zn2+ inhibits more ef-
ficiently hK2 than trypsin activity. There-
fore, trypsin may activate proPSA under cir-
cumstances where hK2 is inhibited.
Whereas trypsinogen is widely expressed
in the various organs of the male genital
tract, PSA and hK2 are expressed only in
the prostate. In the prostate the distribu-
tion of trypsinogen is different from that of
hK2 and PSA. Whereas the latter mainly
are expressed in the secretory cells of the
acini, trypsinogen is mainly found in the
luminal cells of the prostatic excretory
ducts. This suggests that trypsin and PSA
get into contact only when they are admixed
in the prostatic fluid during ejaculation.
PSA is active also in patients with aplasia
of the seminal vesicles and the deferent duct
(Lilja, 1985). This suggests that trypsin
produced in the prostate may be sufficient
for initiation of the proteinase cascade lead-
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ing to activation of both prohK2 and
proPSA. On the other hand, partially
cleaved isoforms of both PSA and hK2 oc-
cur in seminal plasma, and the cleavage sites
that have been identified are typical of
trypsin (Watt et al., 1986; Christensson et
al., 1990; Zhang et al., 1995; Deperthes et
al., 1995; Lövgren et al., 1997; Lövgren et
al., 1999). Thus trypsin may contribute not
only to the activation of prohK2 and
proPSA, but also to their degradation in
seminal plasma.
Adenocarcinoma of the prostate is the
most commonly diagnosed invasive neo-
plasm among males in industrialised coun-
tries (Parkin et al., 1997). Considering the
expression of trypsinogen in other types of
cancer, it will be important to investigate
whether trypsinogen expression is retained
in malignant prostatic epithelial cells. In
preliminary studies we have found that pros-
tate cancer tissue and prostate cancer cell
lines LNCap, DU-145, and PC-3 express
trypsinogen at the mRNA and protein level
(unpublished data).
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Summary and conclusions
Trypsinogen is the most abundant protein
synthesized by the pancreas, reflecting its
pivotal role in protein digestion and in the
activation of other digestive proenzymes.
Trypsinogen and its specific inhibitor PSTI/
TATI have long been considered pancreas-
specific but recent studies have demon-
strated their broad distribution in human
tissues which suggests that they possess sev-
eral biological functions. Trypsinogen and
PSTI/TATI have gained renewed attention
by the identification of mutations in their
genes which have been linked to hereditary
and chronic pancreatitis. Several lines of
evidence also suggest that trypsin may play
a role in tumor invasion by directly degrad-
ing the ECM or by activating other tumor-
associated proteinases, e. g., prouPA and
proMMPs. A role of trypsin and PSTI/TATI
in cancer is also supported by the finding
that PSTI/TATI is a prognostic factor in
ovarian and bladder cancer. The aim of this
work was to study further the expression of
trypsinogen and PSTI/TATI in human tis-
sues and especially in urogenital organs and
their tumors. We also wished to elucidate
the role of trypsin and PSTI/TATI in the
proteolytic activity of tumors.
We first studied the expression of PSTI/
TATI in the kidneys, and found that PSTI/
TATI is expressed in the distal tubules of
normal renal tissue, in renal cell carcinoma
(RCC), and in RCC cell lines which prob-
ably provides an explanation for the eleva-
tion of serum TATI levels in patients with
RCC. We then studied the prognostic value
of TATI in RCC and found that the preop-
erative serum TATI concentration is an in-
dependent prognostic factor in RCC among
all patients and among those with non-
metastatic disease. Therefore, PSTI/TATI
may be used to identify patients with in-
creased risk of aggressive disease that might
benefit from additional treatment modali-
ties.
Little is known about the mechanisms
which control trypsinogen expression in
cancer cells. Doxycycline and chemically
modified tetracyclines (CMTs) are agents
that inhibit cancer cell migration and inva-
sion apparently by inhibiting the expres-
sion and activity of MMPs. Therefore we
studied whether these agents also have an
effect on trypsinogen-2 expression and ac-
tivity. We found that they downregulated
trypsinogen-2 expression in COLO 205
colon adenocarcinoma cells without affect-
ing trypsin-2 activity. We furthermore
found that DOXY, CMTs and TATI inhib-
ited the migration of COLO 205 cells,
which could be induced by the trypsino-
gen-activating enzyme enterokinase. These
results suggest that the ability of DOXY
and CMTs to inhibit tumor invasion may
be mediated by effects on both MMPs and
trypsin.
The gelatinases MMP-2 and MMP-9 are
believed to play a key role in tumor inva-
sion by their ability to degrade type IV
collagen, which is the main component of
the basement membrane. Because human
trypsin-2 activates proMMP-2 and pro-
MMP-9 in vitro we aimed at elucidating
the function of trypsins in vivo by studying
whether the concentrations of trypsinogen-
1 and -2, their α
1
-proteinase inhibitor (API)
complexes, and TATI are related to
proMMP-2 and -9 activation in cyst fluids
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of ovarian tumors. We found that high
trypsinogen and trypsin-API concentra-
tions in ovarian tumor cyst fluids are asso-
ciated with proMMP-9 but not proMMP-
2 activation. We also found that trypsino-
gen and trypsin-API concentrations were
significantly higher in cyst fluids of ma-
lignant than of benign ovarian tumors.
These results suggest that trypsin may play
a role in ovarian tumor invasiveness.
Human seminal plasma contains several
proteolytic enzymes including prostate-spe-
cific antigen (PSA) which dissolves the
sperm-entrapping gel formed immediately
after ejaculation and thus releases motile
sperm. Bovine trypsin and recombinant
human kallikrein-2 (hK2) activate the
proform of PSA in vitro but the physiologi-
cal activators of proPSA are not known. In
the present study we show for the first time
that trypsinogen-1 and -2 are widely ex-
pressed in the male genital tract and that
they occur at high concentrations in semi-
nal fluid. Furthermore, we show that
trypsin-1 and -2 purified from human semi-
nal fluid activate proPSA in vitro. These
findings suggest that trypsins may play a
role in reproduction.
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